<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1303257045
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREVENAR 13 PRE-FILLED SYRINGE VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PNEUMOCOCCAL POLYSACHARIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        245.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AL02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Prevenar&nbsp;13 is a pneumococcal vaccine given to:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>children from 6 weeks to 17 years</strong> to help protect against diseases such as: meningitis (inflammation around the brain), sepsis or bacteraemia (bacteria in the blood stream), pneumonia (lung infection) and ear infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>adults aged 18 years and older</strong> to help prevent disease such as: pneumonia (lung infection), sepsis or bacteraemia (bacteria in the blood stream) and meningitis (inflammation around the brain),</p><p>caused by 13 types of the bacteria <em>Streptococcus pneumoniae.</em></p><p>&nbsp;</p><p>Prevenar&nbsp;13, provides protection against 13 types of <em>Streptococcus pneumoniae</em> bacteria, and replaces Prevenar, which provided protection against 7 types.</p><p>&nbsp;</p><p>The vaccine works by helping the body to make its own antibodies, which protect you or your child against these diseases.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Prevenar&nbsp;13 should not be given:</strong></p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp; if you or your child is allergic (hypersensitive) to the active substances or to any of the other ingredients in this medicine (listed in section 6) or to any other vaccine that contains diphtheria toxoid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or your child has a severe infection with a high temperature (over 38&deg;C). If this applies to you or your child, then the vaccination will be postponed until you or your child is feeling better. A minor infection, such as a cold, should not be a problem. However, talk to your doctor, pharmacist, or nurse first.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor, pharmacist, or nurse before the vaccination if you or your child:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has any present or past medical problems after any dose of Prevenar or Prevenar&nbsp;13 such as an allergic reaction or problems with breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has any bleeding problems or bruises easily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has a weakened immune system (such as due to HIV infection), you/she/he may not get the full benefit from Prevenar&nbsp;13.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has experienced seizures as medicines to lower fever may need to be taken before Prevenar 13 is given. If your child should become unresponsive or experience seizures (fits) after the vaccination, please contact your doctor immediately. See also section 4.</p><p>&nbsp;</p><p>Talk to your doctor, pharmacist, or nurse before the vaccination if your child was born very prematurely (at or before 28 weeks of gestation), as longer gaps than normal between breaths may occur for 2-3 days after vaccination. See also section 4.</p><p>&nbsp;</p><p>As with any vaccine, Prevenar&nbsp;13 will not protect all persons who are vaccinated.</p><p>&nbsp;</p><p>Prevenar&nbsp;13 will only protect against ear infections in children caused by the types of <em>Streptococcus pneumoniae</em> for which the vaccine has been developed. It will not protect against other infectious agents that can cause ear infections.</p><p>&nbsp;</p><p><strong>Other medicines/vaccines and Prevenar&nbsp;13</strong></p><p><strong>&nbsp;</strong></p><p>Your doctor may ask you to give your child paracetamol or other medicines that lower fever before</p><p>Prevenar&nbsp;13 is given. This will help to lower some of the side effects of Prevenar&nbsp;13.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you or your child is taking, has recently taken or might take any other medicines, or has recently received any other vaccine.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>&nbsp;</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before receiving this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Prevenar&nbsp;13 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4 &ldquo;Possible side effects&rdquo; may temporarily affect the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Prevenar&nbsp;13 contains sodium</strong></p><p><strong>&nbsp;</strong></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor or nurse will inject the recommended dose (0.5&nbsp;ml) of the vaccine into your arm or your child&#39;s arm or leg muscle.</p><p>&nbsp;</p><p><u>Infants aged 6 weeks to 6&nbsp;months of age</u></p><p>&nbsp;</p><p>Typically, your child should receive an initial course of three injections of the vaccine followed by a booster dose.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first injection may be given from the age of six weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each injection will be given at least one month apart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fourth injection (booster) will be given between 11 and 15&nbsp;months of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be told when your child should come back for the next injection.</p><p>&nbsp;</p><p>According to official recommendations in your country, an alternative schedule may be used by your healthcare provider. Please speak to your doctor, pharmacist, or nurse for more information.</p><p>&nbsp;</p><p><u>Premature infants </u></p><p>&nbsp;</p><p>Your child will receive an initial course of three injections. The first injection may be given as early as six weeks of age with at least one month between doses. Between 11 and 15&nbsp;months of age, your child will receive a fourth injection (booster).</p><p><u>&nbsp;</u></p><p><u>Unvaccinated infants, children, and adolescents over 7&nbsp;months of age</u></p><p>&nbsp;</p><p>Infants aged <strong>7 to 11&nbsp;months </strong>should receive two injections. Each injection will be given at least one month apart. A third injection will be given in the second year of life.</p><p>&nbsp;</p><p>Children aged <strong>12 to 23&nbsp;months</strong> should receive two injections. Each injection will be given at least two months apart.</p><p>&nbsp;</p><p>Children aged <strong>2 to 17&nbsp;years</strong> should receive one injection.</p><p>&nbsp;</p><p><u>Infants, children, and adolescents previously vaccinated with Prevenar</u></p><p>&nbsp;</p><p>Infants and children who have previously received Prevenar may receive Prevenar&nbsp;13 to complete the course of injections.</p><p>&nbsp;</p><p>For children <strong>1 to 5&nbsp;years</strong> of age previously vaccinated with Prevenar, your doctor or nurse will recommend how many injections of Prevenar&nbsp;13 are required.</p><p>&nbsp;</p><p>Children and adolescents <strong>6 to 17&nbsp;years</strong> of age should receive one injection.</p><p>&nbsp;</p><p>It is important to follow the instructions from the doctor, pharmacist, or nurse so that your child completes the course of injections.</p><p>&nbsp;</p><p>If you forget to go back at the scheduled time, ask the doctor, pharmacist, or nurse for advice.</p><p>&nbsp;</p><p><u>Adults</u></p><p>&nbsp;</p><p>Adults should receive one injection.</p><p>&nbsp;</p><p>Tell your doctor, pharmacist or nurse if you have been given a pneumococcal vaccine before.</p><p><u>&nbsp;</u></p><p>If you have any further questions on the use of Prevenar&nbsp;13, ask your doctor, pharmacist, or nurse.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><u>&nbsp;</u></p><p>Individuals considered to be at a higher risk of pneumococcal infection (such as those with sickle cell disease or HIV infection), including those previously vaccinated with the 23‑valent pneumococcal polysaccharide vaccine, may receive at least one dose of Prevenar&nbsp;13.</p><p>&nbsp;</p><p>Individuals with a blood-forming stem cell transplant may receive three injections, with the first given at 3&nbsp;to&nbsp;6&nbsp;months after the transplant and with an interval of at least 1 month between doses. A fourth injection (booster) is recommended 6 months after the third injection.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines, Prevenar&nbsp;13 can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;13 in infants and children (6&nbsp;weeks to 5&nbsp;years of age):</strong></p><p>&nbsp;</p><p><strong>The most common side effects</strong> (these may occur with more than 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever; irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness; restless sleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, hardness, swelling at the vaccination-site of 2.5&nbsp;cm -7.0&nbsp;cm (after the booster dose and in older children [aged 2 to 5&nbsp;years])</p><p>&nbsp;</p><p><strong>Common side effects</strong> (these may occur with up to 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever of more than&nbsp;39&deg;C; tenderness at the vaccination-site interfering with movement, redness, hardness, swelling at the vaccination-site of 2.5&nbsp;cm -7.0&nbsp;cm (after the initial course of injections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (these may occur with up to 1 in 100 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (or fits), including those caused by a high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria or urticaria-like rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, swelling, or hardness at the vaccination-site of more than&nbsp;7&nbsp;cm; crying</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (these may occur with up to 1 in 1,000 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collapse or shock-like state (hypotonic-hyporesponsive episode)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;13 in children and adolescents (6 to 17 years of age):</strong></p><p>&nbsp;</p><p><strong>The most common side effects</strong> (these may occur with more than 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness; restless sleep; tenderness at the vaccination-site interfering with movement</p><p>&nbsp;</p><p><strong>Common side effects</strong> (these may occur with up to 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash; hives (urticaria or urticaria-like rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&nbsp;</p><p>Children and adolescents with either HIV infection, sickle cell disease or a blood-forming stem cell transplant had similar side effects however the frequencies of headaches, vomiting, diarrhoea, fever, fatigue, joint and muscle pain were very common.</p><p>&nbsp;</p><p>In babies born very prematurely (at or before 28 weeks of gestation), longer gaps than normal between breaths may occur for 2‑3 days after vaccination.</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;13 in adults:</strong></p><p><strong>&nbsp;</strong></p><p><strong>The most common side effects</strong> (these may occur with more than 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite; headaches; diarrhoea; vomiting (for those 18 to 49 years of age)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills; tiredness; rash; pain, redness, swelling hardness or tenderness at the vaccination-site, interfering with arm movement (severe pain or tenderness at vaccination-site for those 18‑39&nbsp;years of age and severe limitation of arm movements for those 18 to 39 years of age)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening or new pain in your joints, worsening or new pain in your muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (for those 18 to 29 years of age)</p><p>&nbsp;</p><p><strong>Common side effects</strong> (these may occur with up to 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (for those 50 years and older); fever (for those 30 years and older)</p><p><em>&nbsp;</em></p><p><strong>Uncommon side effects</strong> (these may occur with up to 1 in 100 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination-site, such as under the arm</p><p>&nbsp;</p><p>Adults with HIV infection had similar side effects however the frequencies were very common for fever, vomiting and common for nausea.</p><p>&nbsp;</p><p>Adults with a blood-forming stem cell transplant had similar side effects however the frequencies were very common for fever and vomiting.</p><p>&nbsp;</p><p><strong>The following additional side effects have been seen with Prevenar&nbsp;13 in postmarketing experience </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction including shock (cardiovascular collapse); angioedema (swelling of lips, face or throat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria), redness and irritation (dermatitis) and itching (pruritus) at the vaccination-site; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination-site, such as under the arm or in the groin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rash causing itchy red blotches (erythema multiforme)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you or your child get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call Center: 19999</p><ul><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>Like all vaccines, Prevenar&nbsp;13 can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;13 in infants and children (6&nbsp;weeks to 5&nbsp;years of age):</strong></p><p>&nbsp;</p><p><strong>The most common side effects</strong> (these may occur with more than 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever; irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness; restless sleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, hardness, swelling at the vaccination-site of 2.5&nbsp;cm -7.0&nbsp;cm (after the booster dose and in older children [aged 2 to 5&nbsp;years])</p><p>&nbsp;</p><p><strong>Common side effects</strong> (these may occur with up to 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever of more than&nbsp;39&deg;C; tenderness at the vaccination-site interfering with movement, redness, hardness, swelling at the vaccination-site of 2.5&nbsp;cm -7.0&nbsp;cm (after the initial course of injections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (these may occur with up to 1 in 100 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (or fits), including those caused by a high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria or urticaria-like rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, swelling, or hardness at the vaccination-site of more than&nbsp;7&nbsp;cm; crying</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (these may occur with up to 1 in 1,000 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collapse or shock-like state (hypotonic-hyporesponsive episode)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;13 in children and adolescents (6 to 17 years of age):</strong></p><p>&nbsp;</p><p><strong>The most common side effects</strong> (these may occur with more than 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness; restless sleep; tenderness at the vaccination-site interfering with movement</p><p>&nbsp;</p><p><strong>Common side effects</strong> (these may occur with up to 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash; hives (urticaria or urticaria-like rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&nbsp;</p><p>Children and adolescents with either HIV infection, sickle cell disease or a blood-forming stem cell transplant had similar side effects however the frequencies of headaches, vomiting, diarrhoea, fever, fatigue, joint and muscle pain were very common.</p><p>&nbsp;</p><p>In babies born very prematurely (at or before 28 weeks of gestation), longer gaps than normal between breaths may occur for 2‑3 days after vaccination.</p><p>&nbsp;</p><p><strong>The following side effects include those reported for Prevenar&nbsp;13 in adults:</strong></p><p><strong>&nbsp;</strong></p><p><strong>The most common side effects</strong> (these may occur with more than 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite; headaches; diarrhoea; vomiting (for those 18 to 49 years of age)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills; tiredness; rash; pain, redness, swelling hardness or tenderness at the vaccination-site, interfering with arm movement (severe pain or tenderness at vaccination-site for those 18‑39&nbsp;years of age and severe limitation of arm movements for those 18 to 39 years of age)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening or new pain in your joints, worsening or new pain in your muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (for those 18 to 29 years of age)</p><p>&nbsp;</p><p><strong>Common side effects</strong> (these may occur with up to 1 in 10 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (for those 50 years and older); fever (for those 30 years and older)</p><p><em>&nbsp;</em></p><p><strong>Uncommon side effects</strong> (these may occur with up to 1 in 100 doses of the vaccine) are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination-site, such as under the arm</p><p>&nbsp;</p><p>Adults with HIV infection had similar side effects however the frequencies were very common for fever, vomiting and common for nausea.</p><p>&nbsp;</p><p>Adults with a blood-forming stem cell transplant had similar side effects however the frequencies were very common for fever and vomiting.</p><p>&nbsp;</p><p><strong>The following additional side effects have been seen with Prevenar&nbsp;13 in postmarketing experience </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction including shock (cardiovascular collapse); angioedema (swelling of lips, face or throat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria), redness and irritation (dermatitis) and itching (pruritus) at the vaccination-site; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination-site, such as under the arm or in the groin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rash causing itchy red blotches (erythema multiforme)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you or your child get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call Center: 19999</p><ul><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;<br />&nbsp;</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are polysaccharide CRM<sub>197</sub> conjugates consisting of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2&nbsp;&micro;g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.4&nbsp;&micro;g of polysaccharide for serotype 6B</p><p>&nbsp;</p><p>1 dose (0.5 ml) contains approximately 32 &micro;g CRM<sub>197</sub> carrier protein, adsorbed on aluminium phosphate (0.125&nbsp;mg aluminium).</p><p>&nbsp;</p><p>The other ingredients are sodium chloride, succinic acid, polysorbate 80 and water for injections.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The vaccine is a white suspension for injection, provided in a single-dose, pre-filled syringe (0.5 ml). Pack sizes of 1 and 10, with or without needle, and a multipack each containing 5 packs of 10 pre filled syringes, with or without needle. Not all pack sizes may be marketed.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORISATION HOLDER</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p>Pfizer Europe MA EEIG, Belgium</p><p><strong>Manufactured by:</strong></p><p>Pfizer Ireland Pharmaceuticals,</p><p>Grange Castle Business Park,</p><p>Clondalkin, Dublin 22,</p><p>Ireland</p><p><strong>&nbsp;</strong></p><p><strong>Packed &amp; released by</strong>:</p><p>Pfizer Manufacturing Belgium NV</p><p>Rijksweg 12</p><p>2870, Puurs, Belgium</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بريفينار 13 هو لقاح للمكورات الرئوية، ويتم إعطاؤه في الحالات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأطفال من عمر 6 أسابيع وحتى 17 عامًا</strong> للمساعدة في الوقاية من الإصابة بأمراض مثل: التهاب السحايا (التهاب الأغشية المحيطة بالدماغ) أو الإنتان أو تجرثم الدم (وجود بكتيريا في مجرى الدم) والالتهاب الرئوي (عدوى بالرئة) وعدوى الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>البالغين من عمر 18 عامًا وأكبر</strong> للمساعدة في منع الإصابة بأمراض مثل: الالتهاب الرئوي (عدوى بالرئة) أو الإنتان أو تجرثم الدم (وجود بكتيريا في مجرى الدم) والتهاب السحايا (التهاب الأغشية المحيطة بالدماغ)،</p><p dir="RTL">التي يسببها 13 نوعًا من بكتيريا <em>المكورات العقدية الرئوية (ستريبتوكوكس نومونيا)</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوفر بريفينار 13 الوقاية من 13 نوعًا من بكتيريا <em>المكورات العقدية الرئوية</em>، وهو يحل محل لقاح بريفينار الذي يوفر الوقاية من 7 أنواع فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعمل اللقاح عن طريق مساعدة الجسم على إنتاج الأجسام المضادة الخاصة به، التي تحميك أنت أو طفلك من هذه الأمراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>موانع استعمال بريفينار 13:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا كنت أنت، أو كان طفلك، مصابًا بالحساسية (فرط الحساسية) تجاه المواد الفعالة أو أي من المكونات الأخرى الموجودة في هذا الدواء (المدرجة في القسم 6) أو تجاه أي لقاح آخر يحتوي على أشباه سموم الدفتريا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت، أو كان طفلك، مصابًا بعدوى شديدة مصحوبة بارتفاع في درجة الحرارة (تزيد عن 38 درجة مئوية). إذا انطبق ذلك عليك أو على طفلك، فسيتم تأجيل التطعيم حتى تتحسن حالتك أو حالة طفلك. أما حالات العدوى البسيطة، كالبرد مثلًا، فهي لا تمثل مشكلة. ومع ذلك، تحدث مع طبيبك أو الصيدلي أو الممرضة أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;-&nbsp;&nbsp;&nbsp; </strong><strong>الا</strong><strong>لا</strong><strong>حتياطات عند استعمال بريفينار</strong><strong> 13</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل التطعيم إذا كنت، أنت أو طفلك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني حاليًا أو سبق أن عانيت من أي مشكلات صحية بعد تلقي أي جرعة من بريفينار أو بريفينار 13، كالإصابة بتفاعل حساسية أو مشكلات تنفسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من أي مشكلات نزفية أو تتكدم بسهولة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ضعف الجهاز المناعي (نتيجة للإصابة بعدوى فيروس نقص المناعة البشرية (HIV) على سبيل المثال)، فقد لا تستفيد/يستفيد طفلك بشكل كامل من لقاح بريفينار 13.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعرضت لنوبات، حيث قد يلزم تناول أدوية خفض الحمى قبل إعطاء بريفينار 13. في حالة عدم استجابة طفلك أو إصابته بنوبات بعد تلقي التطعيم، يُرجى التواصل مع طبيبك على الفور. انظر أيضًا القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل التطعيم إذا كان طفلك قد وُلِد قبل أوانه بكثير (أي عند مرور 28 أسبوعًا من الحمل أو قبل ذلك)، حيث قد يعاني لمدة يومين إلى 3 أيام بعد التطعيم من استطالة في الفترة الزمنية بين التنفس والآخر بشكل أكثر من الطبيعي. انظر أيضًا القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وكما هو الحال بالنسبة لأي لقاح، فإن بريفينار 13 لن يقي جميع الأشخاص الذين يتلقوه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يساعد بريفينار 13 فقط في الوقاية من عدوى الأذن لدى الأطفال، التي تسببها أنواع بكتيريا <em>المكورات العقدية الرئوية</em> التي تم تطوير هذا اللقاح لمكافحتها. ولكنه لن يقي من العوامل المعدية الأخرى التي قد تسبب عدوى الأذن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يطلب منك طبيبك إعطاء طفلك باراسيتامول أو أي أدوية أخرى خافضة للحمى قبل</p><p dir="RTL">إعطاء بريفينار 13. سيساعد ذلك على تخفيف بعض الآثار الجانبية لبريفينار 13.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت أنت، أو كان طفلك، تتناول حاليًا أو قد تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، أو إذا تلقيت أنت أو طفلك أي لقاح آخر مؤخرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د- الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ- تأثير بريفينار 13 على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يوجد تأثير لبريفينار 13 أو له تأثير لا يذكر على القدرة على القيادة واستخدام الآلات. مع ذلك، فقد تؤثر بعض الآثار المذكورة تحت القسم 4 &quot;الآثار الجانبية المحتملة&quot; بشكل مؤقت على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و- معلومات هامة حول بعض مكونات</strong> <strong>بريفينار 13</strong></p><p dir="RTL"><strong>يحتوي بريفينار 13 على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من 1 مللي مول من الصوديوم (23 ملجم) لكل جرعة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم الطبيب أو الممرضة بحقن الجرعة الموصى بها (0.5 مل) من اللقاح لك أو لطفلك في عضلة الذراع أو الساق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال الرضّع من عمر 6 أسابيع إلى 6 أشهر</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">نموذجيًا، ينبغي أن يتلقى طفلك نظام جرعات أوليًا يتكون من ثلاث حقن من اللقاح تتبعها جرعة معززة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن إعطاء الحقنة الأولى ابتداءً من عمر ستة أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيفصل شهر واحد على الأقل بين كل حقنة والأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم إعطاء حقنة رابعة (الجرعة المعززة) ما بين عمر 11 و15 شهرًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم إبلاغك بالموعد الذي ينبغي على طفلك العودة فيه لتلقي الحقنة التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفقًا للتوصيات الرسمية في بلدك، يمكن أن يتبع مقدم الرعاية الصحية الخاص بك نظامًا بديلًا لإعطاء اللقاحات. يُرجى التحدث مع طبيبك أو الصيدلي أو الممرضة للحصول على المزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال المبتسرون </u></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتلقى طفلك نظام جرعات أوليًا يتكون من ثلاث حقن. قد يتم إعطاء الحقنة الأولى ابتداءً من عمر ستة أسابيع، بحيث يفصل بين الجرعات ما لا يقل عن شهر واحد. في الفترة ما بين 11 و15 شهرًا من العمر، سيتلقى طفلك حقنة رابعة (الجرعة المعززة).</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>مَن لم يسبق تطعيمه من الرُّضع والأطفال الأكبر من عمر 7 أشهر والمراهقين</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي للأطفال الرضع الذين تتراوح أعمارهم بين <strong>7 و11 شهرًا</strong> تلقي حقنتين من اللقاح. سيفصل شهر واحد على الأقل بين كل حقنة والأخرى. سيتم إعطاء حقنة ثالثة في العام الثاني من العمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي للأطفال الذين تتراوح أعمارهم بين <strong>12 و23 شهرًا</strong> تلقي حقنتين من اللقاح. سيفصل بين كل حقنة والأخرى شهران على الأقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يتلقى الأطفال الذين تتراوح أعمارهم بين <strong>عامين و17 عامًا</strong> حقنة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>من سبق تطعيمه ببريفينار من الرضع والأطفال والمراهقين</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن للرضع والأطفال الذين سبق لهم تلقي بريفينار أن يتلقوا بريفينار 13 لإكمال نظام جرعات الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للأطفال الذين تتراوح أعمارهم بين <strong>عام واحد و5 أعوام</strong> والذين سبق لهم التطعيم بلقاح بريفينار، سيوصي طبيبك أو الممرضة بعدد مرات الحقن اللازم تلقيه من بريفينار 13.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يتلقى الأطفال والمراهقون الذين تتراوح أعمارهم بين 6 و17 عامًا جرعة حقن واحدة من اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم اتباع تعليمات الطبيب أو الصيدلي أو الممرضة حتى يستكمل طفلك نظام جرعات الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ما نسيت العودة في الموعد المحدد، فاطلب المشورة من الطبيب أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يتلقى البالغين حقنة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا ما سبق أن تلقيت لقاح مكورات رئوية من قبل.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">إذا كانت لديك أي اسئلة أخرى حول استخدام بريفينار 13، فاسأل طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الفئات الخاصة من المرضى</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">يُمكن للأفراد الأكثر عرضة لخطر الإصابة بعدوى المكورات الرئوية (مثل أولئك المصابين بمرض فقر الدم المنجلي أو بعدوى فيروس HIV)، بما في ذلك أولئك الذين سبق لهم التطعيم بلقاح المكورات الرئوية عديد السكاريد الجامع لـ23 سلالة، أن يتلقوا جرعة واحدة على الأقل من بريفينار 13.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يتلقى الأشخاص الذين خضعوا لزرع خلايا جذعية مكونة للدم ثلاث حقن، حيث يتم إعطاء الحقنة الأولى بعد مرور 3 إلى 6 أشهر بعد الزرع، على أن يفصل بين الجرعات شهر واحد على الأقل. يُوصى بتلقي حقنة رابعة (الجرعة المعززة) بعد مرور 6 أشهر على الحقنة الثالثة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لجميع اللقاحات، قد يسبب بريفينار ١٣ أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي تم الإبلاغ عن حدوثها عند إعطاء بريفينار ١٣ للرضع والأطفال (من عمر ٦ أسابيع إلى ٥ أعوام):</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا</strong> (التي قد تحدث مع ما يزيد عن جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، التهيج، الألم أو التوجع أو الاحمرار أو التورم أو التيبس في موضع حقن اللقاح، النعاس، اضطراب النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تيبس أو تورم في موضع حقن اللقاح مساحته تتراوح بين ٢,٥ و٧,٠ سم (بعد تلقي الجرعة المعززة ولدى الأطفال الأكبر سنًا [من عمر ٢ إلى ٥ أعوام])</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى التي تزيد عن ٣٩ درجة مئوية، الشعور بتوجع في موضع حقن اللقاح يعيق الحركة، احمرار أو تيبس أو تورم في موضع حقن اللقاح مساحته تتراوح بين ٢,٥ و٧,٠ سم (نظام جرعات الحقن الأولي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠٠ جرعة من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات، بما في ذلك تلك الناتجة عن ارتفاع درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الارتيكاريا أو الطفح الجلدي الشبيه بالارتيكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تورم أو تيبس في موضع حقن اللقاح، مساحته تزيد عن ٧ سم؛ البكاء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية النادرة </strong>(التي قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠٠٠ جرعة من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوهط (الهبوط) أو الدخول في حالة تشبه الصدمة (نوبة من نقص الاستجابة ونقص التوتر العضلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بتفاعل حساسية (فرط الحساسية)، بما في ذلك تورم الوجه و/أو الشفتين، صعوبة التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي تم الإبلاغ عن حدوثها عند إعطاء بريفينار ١٣ للأطفال والمراهقين (من عمر ٦ أعوام إلى ١٧ عامًا):</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا</strong> (التي قد تحدث مع ما يزيد عن جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج، ألم أو توجع موضع حقن اللقاح أو احمراره أو تورمه أو تيبسه، النعاس، اضطراب النوم، الشعور بتوجع في موضع حقن اللقاح يعيق الحركة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الشرى (الارتيكاريا أو الطفح الجلدي الشبيه بالارتيكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&nbsp;</p><p dir="RTL">أصيب الأطفال والمراهقون المصابون بعدوى فيروس نقص المناعة البشرية (HIV) أو بداء فقر الدم المنجلي أو الذين خضعوا لزرع خلايا جذعية مكونة للدم بأعراض جانبية مماثلة، إلا أن معدلات حدوث حالات الصداع والقيء والإسهال والحمى والإرهاق وألم المفاصل والعضلات كانت شائعة للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال المولودين قبل أوانهم بكثير (أي عند مرور ٢٨ أسبوعًا من الحمل أو قبل ذلك)، قد يعانون لمدة يومين إلى ثلاثة أيام بعد التطعيم من استطالة في الفترة الزمنية بين التنفس والآخر بشكل أكثر من الطبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي أبلغ بها عند إعطاء بريفينار ١٣ للبالغين:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا</strong> (التي قد تحدث مع ما يزيد عن جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية، الصداع، الإسهال، القيء (أصيب بها من يبلغون ١٨ إلى ٤٩ عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة، التعب، الطفح الجلدي، الألم أو الاحمرار أو التورم أو التيبس أو التوجع في موضع حقن اللقاح ويؤثر على حركة الذراع (ألم أو توجع شديد في موضع الحقن بالنسبة للبالغين من العمر ١٨إلى ٣٩ عامًا، وإعاقة شديدة لحركات الذراع للبالغين من العمر ١٨ إلى ٣٩ عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالألم أو تفاقم الألم الموجود بالفعل في المفاصل أو العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (للبالغين من العمر ١٨ إلى ٢٩ عامًا)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء (للبالغين من العمر ٥٠ عامًا فأكبر)، الحمى (للبالغين من العمر ٣٠ عامًا فأكبر)</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠٠ جرعة من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بتفاعل حساسية (فرط الحساسية)، بما في ذلك تورم الوجه و/أو الشفتين، صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد أو الغدد الليمفاوية (اعتلال الغدد الليمفاوية) القريبة من موضع حقن اللقاح، كتلك الموجودة تحت الإبط</p><p dir="RTL">&nbsp;</p><p dir="RTL">أصيب البالغون المصابون بعدوى فيروس HIV بأعراض جانبية مماثلة، إلا أن معدلات الإصابة بالحمى والقيء كانت شائعة للغاية، بينما كانت معدلات الإصابة بالغثيان شائعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أصيب البالغون الذين خضعوا لزرع خلايا جذعية مكونة للدم بأعراض جانبية مماثلة، إلا أن معدلات الإصابة بالحمى والقيء كانت شائعة للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظت الأعراض الجانبية الإضافية التالية عند إعطاء بريفينار </strong><strong>١</strong><strong>٣ </strong><strong>في تجربة ما بعد التسويق </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد بما في ذلك الصدمة (الوهط القلبي الوعائي)، الوذمة الوعائية (تورم الشفتين أو الوجه أو الحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالشرى (الارتيكاريا) والاحمرار والتهيج (التهاب الجلد) والحكة بموضع حقن اللقاح، احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد أو الغدد الليمفاوية (اعتلال الغدد الليمفاوية) القريبة من موضع حقن اللقاح، كتلك الموجودة تحت الإبط أو في الأُربيَّة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يسبب وجود بقع حمراء مثيرة للحكة (بقع حمراء عديدة الأشكال)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت أنت أو طفلك بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنكِ المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL"><strong>&nbsp;</strong>مركز الاتصال الموحد: ۱۹۹۹۹البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني:<strong> </strong>www.sfda.gov.sa/npc</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لجميع اللقاحات، قد يسبب بريفينار ١٣ أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي تم الإبلاغ عن حدوثها عند إعطاء بريفينار ١٣ للرضع والأطفال (من عمر ٦ أسابيع إلى ٥ أعوام):</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا</strong> (التي قد تحدث مع ما يزيد عن جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، التهيج، الألم أو التوجع أو الاحمرار أو التورم أو التيبس في موضع حقن اللقاح، النعاس، اضطراب النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تيبس أو تورم في موضع حقن اللقاح مساحته تتراوح بين ٢,٥ و٧,٠ سم (بعد تلقي الجرعة المعززة ولدى الأطفال الأكبر سنًا [من عمر ٢ إلى ٥ أعوام])</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى التي تزيد عن ٣٩ درجة مئوية، الشعور بتوجع في موضع حقن اللقاح يعيق الحركة، احمرار أو تيبس أو تورم في موضع حقن اللقاح مساحته تتراوح بين ٢,٥ و٧,٠ سم (نظام جرعات الحقن الأولي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠٠ جرعة من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات، بما في ذلك تلك الناتجة عن ارتفاع درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الارتيكاريا أو الطفح الجلدي الشبيه بالارتيكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تورم أو تيبس في موضع حقن اللقاح، مساحته تزيد عن ٧ سم؛ البكاء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية النادرة </strong>(التي قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠٠٠ جرعة من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوهط (الهبوط) أو الدخول في حالة تشبه الصدمة (نوبة من نقص الاستجابة ونقص التوتر العضلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بتفاعل حساسية (فرط الحساسية)، بما في ذلك تورم الوجه و/أو الشفتين، صعوبة التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي تم الإبلاغ عن حدوثها عند إعطاء بريفينار ١٣ للأطفال والمراهقين (من عمر ٦ أعوام إلى ١٧ عامًا):</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا</strong> (التي قد تحدث مع ما يزيد عن جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج، ألم أو توجع موضع حقن اللقاح أو احمراره أو تورمه أو تيبسه، النعاس، اضطراب النوم، الشعور بتوجع في موضع حقن اللقاح يعيق الحركة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الشرى (الارتيكاريا أو الطفح الجلدي الشبيه بالارتيكاريا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&nbsp;</p><p dir="RTL">أصيب الأطفال والمراهقون المصابون بعدوى فيروس نقص المناعة البشرية (HIV) أو بداء فقر الدم المنجلي أو الذين خضعوا لزرع خلايا جذعية مكونة للدم بأعراض جانبية مماثلة، إلا أن معدلات حدوث حالات الصداع والقيء والإسهال والحمى والإرهاق وألم المفاصل والعضلات كانت شائعة للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال المولودين قبل أوانهم بكثير (أي عند مرور ٢٨ أسبوعًا من الحمل أو قبل ذلك)، قد يعانون لمدة يومين إلى ثلاثة أيام بعد التطعيم من استطالة في الفترة الزمنية بين التنفس والآخر بشكل أكثر من الطبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الأعراض الجانبية التالية تلك التي أبلغ بها عند إعطاء بريفينار ١٣ للبالغين:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأكثر شيوعًا</strong> (التي قد تحدث مع ما يزيد عن جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية، الصداع، الإسهال، القيء (أصيب بها من يبلغون ١٨ إلى ٤٩ عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة، التعب، الطفح الجلدي، الألم أو الاحمرار أو التورم أو التيبس أو التوجع في موضع حقن اللقاح ويؤثر على حركة الذراع (ألم أو توجع شديد في موضع الحقن بالنسبة للبالغين من العمر ١٨إلى ٣٩ عامًا، وإعاقة شديدة لحركات الذراع للبالغين من العمر ١٨ إلى ٣٩ عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالألم أو تفاقم الألم الموجود بالفعل في المفاصل أو العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (للبالغين من العمر ١٨ إلى ٢٩ عامًا)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠ جرعات من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء (للبالغين من العمر ٥٠ عامًا فأكبر)، الحمى (للبالغين من العمر ٣٠ عامًا فأكبر)</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة</strong> (قد تحدث مع ما يصل إلى جرعة واحدة من كل ١٠٠ جرعة من اللقاح) هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بتفاعل حساسية (فرط الحساسية)، بما في ذلك تورم الوجه و/أو الشفتين، صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد أو الغدد الليمفاوية (اعتلال الغدد الليمفاوية) القريبة من موضع حقن اللقاح، كتلك الموجودة تحت الإبط</p><p dir="RTL">&nbsp;</p><p dir="RTL">أصيب البالغون المصابون بعدوى فيروس HIV بأعراض جانبية مماثلة، إلا أن معدلات الإصابة بالحمى والقيء كانت شائعة للغاية، بينما كانت معدلات الإصابة بالغثيان شائعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أصيب البالغون الذين خضعوا لزرع خلايا جذعية مكونة للدم بأعراض جانبية مماثلة، إلا أن معدلات الإصابة بالحمى والقيء كانت شائعة للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظت الأعراض الجانبية الإضافية التالية عند إعطاء بريفينار </strong><strong>١</strong><strong>٣ </strong><strong>في تجربة ما بعد التسويق </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد بما في ذلك الصدمة (الوهط القلبي الوعائي)، الوذمة الوعائية (تورم الشفتين أو الوجه أو الحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالشرى (الارتيكاريا) والاحمرار والتهيج (التهاب الجلد) والحكة بموضع حقن اللقاح، احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم العقد أو الغدد الليمفاوية (اعتلال الغدد الليمفاوية) القريبة من موضع حقن اللقاح، كتلك الموجودة تحت الإبط أو في الأُربيَّة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يسبب وجود بقع حمراء مثيرة للحكة (بقع حمراء عديدة الأشكال)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت أنت أو طفلك بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنكِ المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL"><strong>&nbsp;</strong>مركز الاتصال الموحد: ۱۹۹۹۹البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني:<strong> </strong>www.sfda.gov.sa/npc</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية والملصق بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في مُبرِّد (من درجتين&deg; - &deg;8 درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بتجميده.</p><p dir="RTL">&nbsp;<br />&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي المركبان عديدا السكاريد المقترنان بـ CRM<sub>197</sub>ويتكونان من:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2 ميكروجرام من عديد السكاريد للأنماط المصلية 1 و3 و4 و5 و6A و7F و9V و14 و18C و19A و19F و23F</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.4 ميكروجرام من عديد السكاريد للنمط المصلي 6B</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي جرعة واحدة (0.5 مل) على 32 ميكروجرامًا تقريبًا من البروتين الحامل CRM<sub>197</sub> مُمتزة على فوسفات الألومنيوم (0.125 ملجم من الألومنيوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي كلوريد الصوديوم وحمض السكسينيك وبولي سوربات 80 وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يأتي&nbsp;</strong>اللقاح في صورة مُعلق أبيض اللون مخصص للحقن، معبأ في محقنة مسبقة التعبئة مُخصصة لإعطاء جرعة واحدة (سعة 0.5 مل). توجد عبوات بأحجام تحتوي على محقنة واحدة و10 محاقن، مزودة بإبرة أو غير مزودة بها، وعبوات كبيرة الحجم تحتوي كل منها على 5 عبوات بها 10 محاقن مسبقة التعبئة مزودة بإبرة أو غير مزودة بها. قد لا يتم طرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ج&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مالك تصريح التسويق</strong></p><p dir="RTL">Pfizer Europe MA EEIG, Belgium، بلجيكا</p><p dir="RTL"><strong>تم تصنيعه بواسطة:</strong></p><p dir="RTL">Pfizer Ireland Pharmaceuticals,</p><p dir="RTL">Grange Castle Business Park,</p><p dir="RTL">Clondalkin, Dublin 22,</p><p dir="RTL">Ireland، أيرلندا</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>تمت تعبئته وتوزيعه بواسطة</strong>:</p><p dir="RTL">Pfizer Manufacturing Belgium NV</p><p dir="RTL">Rijksweg 12</p><p dir="RTL">2870, Puurs, Belgium&nbsp; بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prevenar 13 suspension for injection
pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 dose (0.5 ml) contains:

Pneumococcal polysaccharide serotype 11	2.2 µg
Pneumococcal polysaccharide serotype 31	2.2 µg
Pneumococcal polysaccharide serotype 41	2.2 µg
Pneumococcal polysaccharide serotype 51	2.2 µg
Pneumococcal polysaccharide serotype 6A1	2.2 µg
Pneumococcal polysaccharide serotype 6B1	4.4 µg
Pneumococcal polysaccharide serotype 7F1	2.2 µg
Pneumococcal polysaccharide serotype 9V1	2.2 µg
Pneumococcal polysaccharide serotype 141	2.2 µg
Pneumococcal polysaccharide serotype 18C1	2.2 µg
Pneumococcal polysaccharide serotype 19A1	2.2 µg
Pneumococcal polysaccharide serotype 19F1	2.2 µg
Pneumococcal polysaccharide serotype 23F1	2.2 µg

1Conjugated to CRM197 carrier protein, adsorbed on aluminium phosphate.

1 dose (0.5 ml) contains approximately 32 µg CRM197 carrier protein and 0.125 mg aluminium.

Excipients with known effect
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection.
The vaccine is a homogeneous white suspension.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by <em>Streptococcus pneumoniae</em> in infants, children and adolescents from 6&nbsp;weeks to 17&nbsp;years of age.</p><p>&nbsp;</p><p>Active immunisation for the prevention of invasive disease and pneumonia caused by<em> Streptococcus pneumoniae </em>in adults &ge;18&nbsp;years of age and the elderly.</p><p>&nbsp;</p><p>See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.</p><p>&nbsp;</p><p>The use of Prevenar&nbsp;13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease and pneumonia in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The immunisation schedules for Prevenar&nbsp;13 should be based on official recommendations.</p><p>&nbsp;</p><p>Posology</p><p>&nbsp;</p><p><u>Infants</u><u> </u><u>and</u><u> children aged 6 weeks to 5 years</u></p><p><em>It is recommended that infants who receive a first dose of Prevenar&nbsp;13 complete the vaccination course with Prevenar&nbsp;13.</em></p><p><em>&nbsp;</em></p><p>Infants aged 6 weeks‑6 months</p><p><u>&nbsp;</u></p><p>Three-dose primary series</p><p>The recommended immunisation series consists of four doses, each of 0.5&nbsp;ml. The primary infant series consists of three doses, with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as six weeks of age. The fourth (booster) dose is recommended between 11 and 15 months of age.</p><p>&nbsp;</p><p>Two-dose primary series</p><p>Alternatively, when Prevenar&nbsp;13 is given as part of a routine infant immunisation programme, a series consisting of three doses, each of 0.5&nbsp;ml, may be given. The first dose may&nbsp;be administered from the age of 2 months, with a second dose&nbsp;2 months&nbsp;later. The third (booster) dose is recommended between 11 and 15 months of age (see section 5.1).</p><p>&nbsp;</p><p>Preterm infants (&lt;37 weeks gestation)</p><p>&nbsp;</p><p>In preterm infants, the recommended immunisation series consists of four doses, each of 0.5 ml. The primary infant series consists of three doses, with the first dose given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as six weeks of age. The fourth (booster) dose is recommended between 11 and 15 months of age (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>Unvaccinated infants and children &ge;&nbsp;7 months of age</p><p>&nbsp;</p><p>Infants aged 7‑11 months</p><p>Two doses, each of 0.5&nbsp;ml, with an interval of at least 1 month between doses. A third dose is recommended in the second year of life.</p><p>&nbsp;</p><p>Children aged 12‑23 months</p><p>Two doses, each of 0.5&nbsp;ml, with an interval of at least 2 months between doses (see section 5.1).</p><p>&nbsp;</p><p>Children and adolescents aged 2‑17 years</p><p>One single dose of 0.5&nbsp;ml.</p><p><u>&nbsp;</u></p><p>Prevenar&nbsp;13 vaccine schedule for infants and children previously vaccinated with Prevenar (7-valent) (<em>Streptococcus pneumoniae</em> serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)</p><p>Prevenar&nbsp;13 contains the same 7 serotypes included in Prevenar, using the same carrier protein CRM<sub>197</sub>.</p><p>&nbsp;</p><p>Infants and children who have begun immunisation with Prevenar may switch to Prevenar&nbsp;13 at any point in the schedule.</p><p>&nbsp;</p><p>Young children (12-59 months) completely immunised with Prevenar (7-valent)</p><p>Young children who are considered completely immunised with Prevenar (7-valent) should receive one dose of 0.5 ml of Prevenar&nbsp;13 to elicit immune responses to the 6 additional serotypes. This dose of Prevenar&nbsp;13 should be administered at least 8 weeks after the final dose of Prevenar (7-valent) (see section 5.1).</p><p>&nbsp;</p><p><em>Children and adolescents</em><strong> </strong><em>5&ndash;17 years </em></p><p>Children 5 to 17 years of age may receive a single dose of Prevenar&nbsp;13 if they have been previously vaccinated with one or more doses of Prevenar. This dose of Prevenar&nbsp;13 should be administered at least 8 weeks after the final dose of Prevenar (7-valent) (see section 5.1).</p><p>&nbsp;</p><p>Adults &ge;18 years of age, and the elderly</p><p>&nbsp;</p><p>One single dose.</p><p>The need for revaccination with a subsequent dose of Prevenar&nbsp;13 has not been established.</p><p>Regardless of prior pneumococcal vaccination status, if the use of 23‑valent pneumococcal polysaccharide vaccine is considered appropriate, Prevenar&nbsp;13 should be given first (see sections 4.5 and 5.1).</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><u>&nbsp;</u></p><p>Individuals who have underlying conditions predisposing them to invasive pneumococcal disease (such as sickle cell disease or HIV infection) including those previously vaccinated with one or more doses of 23‑valent pneumococcal polysaccharide vaccine may receive at least one dose of Prevenar&nbsp;13 (see section 5.1).</p><p>&nbsp;</p><p>In individuals with an haematopoietic stem cell transplant (HSCT), the recommended immunisation series consists of four doses of Prevenar&nbsp;13, each of 0.5&nbsp;ml. The primary series consists of three doses, with the first dose given at 3 to 6 months after HSCT and with an interval of at least 1 month between doses. A fourth (booster) dose is recommended 6 months after the third dose (see section 5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>The vaccine should be given by intramuscular injection. The preferred sites are the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients listed in section 6.1, or to diphtheria toxoid.

As with other vaccines, the administration of Prevenar 13 should be postponed in subjects suffering from acute, severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevenar&nbsp;13 must not be administered intravascularly.</p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p>This vaccine should not be given as an intramuscular injection to individuals with thrombocytopaenia or any coagulation disorder that would contraindicate intramuscular injection, but may be given subcutaneously if the potential benefit clearly outweighs the risks (see section 5.1).</p><p>&nbsp;</p><p>Prevenar&nbsp;13 will only protect against <em>Streptococcus pneumoniae</em> serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia, or otitis media. As with any vaccine, Prevenar&nbsp;13 may not protect all individuals receiving the vaccine from pneumococcal disease. For the most recent epidemiological information in your country you should consult with the relevant national organisation.</p><p>&nbsp;</p><p>Individuals with impaired immune responsiveness, whether due to the use of immuno-suppressive therapy, a genetic defect, human immunodeficiency virus (HIV) infection, or other causes, may have reduced antibody response to active immunisation.</p><p>&nbsp;</p><p>Safety and immunogenicity data are available for a limited number of individuals with sickle cell disease, HIV infection, or with an haematopoietic stem cell transplant (see section 5.1). Safety and immunogenicity data for Prevenar&nbsp;13 are not available for individuals in other specific immuno‑compromised groups (e.g., malignancy or nephrotic syndrome) and vaccination should be considered on an individual basis.</p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p>Infants and children aged 6 weeks to 5 years</p><p>&nbsp;</p><p>In clinical studies, Prevenar&nbsp;13 elicited an immune response to all thirteen serotypes included in the vaccine. The immune response for serotype 3 following the booster dose was not increased above the levels seen after the infant vaccination series; the&nbsp;clinical relevance of this observation regarding the induction of serotype 3 immune memory is unknown (see section 5.1).</p><p>&nbsp;</p><p>The proportions of functional antibody responders (OPA titres &ge;&nbsp;1:8) to serotypes 1, 3 and 5 were high. However, the OPA geometric mean titres were lower than those against each of the remaining additional vaccine serotypes; the clinical relevance of this observation for protective efficacy is unknown (see section 5.1).</p><p>&nbsp;</p><p>Limited data have demonstrated that Prevenar 7-valent (three-dose primary series) induces an acceptable immune response in infants with sickle cell disease with a safety profile similar to that observed in non‑high-risk groups (see section 5.1).</p><p>&nbsp;</p><p>Children younger than 2 years old should receive the appropriate-for-age Prevenar&nbsp;13 vaccination series (see section 4.2). The use of pneumococcal conjugate vaccine does not replace the use of 23‑valent pneumococcal polysaccharide vaccines in children &ge;&nbsp;2 years of age with conditions (such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immuno‑compromised) placing them at higher risk for invasive disease due to <em>Streptococcus pneumoniae</em>. Whenever recommended, children at risk who are &ge;&nbsp;24 months of age and already primed with Prevenar&nbsp;13 should receive 23‑valent pneumococcal polysaccharide vaccine. The interval between the 13‑valent pneumococcal conjugate vaccine (Prevenar&nbsp;13) and the 23‑valent pneumococcal polysaccharide vaccine should not be less than 8 weeks. There are no data available to indicate whether the administration of 23-valent pneumococcal polysaccharide vaccine to unprimed children or to children primed with Prevenar&nbsp;13 might result in hyporesponsiveness to further doses of Prevenar&nbsp;13.</p><p>&nbsp;</p><p>The potential risk of apnoea and the need for respiratory monitoring for 48‑72&nbsp;h should be considered when administering the primary immunisation series to very premature infants (born &pound;&nbsp;28 weeks of gestation), and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.</p><p>&nbsp;</p><p>For vaccine serotypes, protection against otitis media is expected to be lower than protection against invasive disease. As otitis media is caused by many organisms other than pneumococcal serotypes represented in the vaccine, protection against all otitis media is expected to be low (see section 5.1).</p><p>&nbsp;</p><p>When Prevenar&nbsp;13 is administered concomitantly with Infanrix hexa (DTPa‑HBV-IPV/Hib), the rates of febrile reactions are similar to those seen with concomitant administration of Prevenar<br />(7-valent) and Infanrix hexa (see section 4.8). Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Prevenar&nbsp;13 and Infanrix hexa (see section 4.8).</p><p>&nbsp;</p><p>Antipyretic treatment should be initiated according to local treatment guidelines for children with seizure disorders or with a prior history of febrile seizures and for all children receiving Prevenar&nbsp;13 simultaneously with vaccines containing whole cell pertussis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infants and children aged 6 weeks to 5 years</p><p>&nbsp;</p><p>Prevenar&nbsp;13 can be given concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular or whole cell pertussis, <em>Haemophilus influenzae</em> type b, inactivated poliomyelitis, hepatitis B (see section 4.4 for guidance on Infanrix hexa), meningococcal serogroup C, measles, mumps, rubella, varicella and rotavirus vaccine.</p><p>&nbsp;</p><p>Prevenar&nbsp;13 can also be given concomitantly between 12-23 months with the tetanus toxoid conjugated meningococcal polysaccharide serogroups A, C, W and Y vaccine to children who have been adequately primed with Prevenar&nbsp;13 (as per local recommendations).</p><p>&nbsp;</p><p>Data from a postmarketing clinical study evaluating the impact of prophylactic use of antipyretics (ibuprofen and paracetamol) on the immune response to Prevenar&nbsp;13 suggest that administration of paracetamol concomitantly or within the same day of vaccination may reduce the immune response to Prevenar&nbsp;13 after the infant series. Responses to the booster dose administered at 12&nbsp;months were unaffected. The clinical significance of this observation is unknown.</p><p>&nbsp;</p><p>Children and adolescents 6 to 17&nbsp;years of age</p><p>&nbsp;</p><p>No data are currently available regarding concomitant use with other vaccines.</p><p>&nbsp;</p><p>Adults 18 to 49&nbsp;years of age</p><p>&nbsp;</p><p>No data are available regarding concomitant use with other vaccines.</p><p><u>&nbsp;</u></p><p><u>Adults aged 50&nbsp;years and older</u></p><p>&nbsp;</p><p>Prevenar&nbsp;13 may be administered concomitantly with the seasonal trivalent inactivated influenza vaccine (TIV).</p><p>&nbsp;</p><p>In two studies conducted in adults aged 50-59 and 65&nbsp;years and older, it was demonstrated that Prevenar&nbsp;13 may be given concomitantly with trivalent inactivated influenza vaccine (TIV). The responses to all three TIV antigens were comparable when TIV was given alone or concomitantly with Prevenar&nbsp;13.</p><p>&nbsp;</p><p>When Prevenar&nbsp;13 was given concomitantly with TIV, the immune responses to Prevenar&nbsp;13 were lower compared to when Prevenar&nbsp;13 was given alone, however, there was no long-term impact on circulating antibody levels.</p><p>&nbsp;</p><p>In a third study in adults aged 50-93 years, it was demonstrated that Prevenar&nbsp;13 may be given concomitantly with the seasonal quadrivalent inactivated influenza vaccine (QIV). The immune responses to all four QIV strains were noninferior when Prevenar&nbsp;13 was given concomitantly with QIV compared to when QIV was given alone.</p><p>&nbsp;</p><p>The immune responses to Prevenar&nbsp;13 were noninferior when Prevenar&nbsp;13 was given concomitantly with QIV compared to when Prevenar&nbsp;13 was given alone. As with concomitant administration with trivalent vaccines, immune responses to some pneumococcal serotypes were lower when both vaccines were given concomitantly.</p><p>&nbsp;</p><p>Concomitant use with other vaccines has not been investigated.</p><p>&nbsp;</p><p>Different injectable vaccines should always be given at different vaccination sites.</p><p>&nbsp;</p><p>Concomitant administration of Prevenar&nbsp;13 and 23‑valent pneumococcal polysaccharide vaccine has not been studied. In clinical studies when Prevenar&nbsp;13 was given 1 year after 23‑valent pneumococcal polysaccharide vaccine the immune responses were lower for all serotypes compared to when Prevenar&nbsp;13 was given to subjects not previously immunised with 23‑valent pneumococcal polysaccharide vaccine. The clinical significance of this is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>&nbsp;</p><p>There are no data from the use of pneumococcal 13‑valent conjugate vaccine in pregnant women. Therefore the use of Prevenar&nbsp;13 should be avoided during pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>&nbsp;</p><p>It is unknown whether pneumococcal 13‑valent conjugate vaccine is excreted in human milk.</p><p>&nbsp;</p><p>Fertility</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Prevenar&nbsp;13 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section&nbsp;4.8 &ldquo;Undesirable effects&rdquo; may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Analysis of postmarketing reporting rates suggests a potential increased risk of convulsions, with or without fever, and HHE when comparing groups which reported use of Prevenar&nbsp;13 with Infanrix&nbsp;hexa to those which reported use of Prevenar&nbsp;13 alone.</p><p>&nbsp;</p><p>Adverse reactions reported in clinical studies or from the postmarketing experience for all age groups are listed in this section per system organ class, in decreasing order of frequency and seriousness. The frequency is defined as follows: very common (&sup3;&nbsp;1/10), common (&sup3;&nbsp;1/100 to&nbsp;&lt;&nbsp;1/10), uncommon (&sup3;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare&nbsp;(&sup3;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from available data).</p><p>&nbsp;</p><p>Infants and children aged 6 weeks to 5 years</p><p>The safety of the vaccine was assessed in controlled clinical studies where 14,267 doses were given to 4,429 healthy infants from 6 weeks of age at first vaccination and 11‑16 months of age at booster dose. In all infant studies, Prevenar&nbsp;13 was co-administered with routine paediatric vaccines (see section 4.5).</p><p>&nbsp;</p><p>Safety in 354 previously unvaccinated children (7&nbsp;months to 5&nbsp;years of age) was also assessed.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions in children 6&nbsp;weeks to 5&nbsp;years of age were vaccination-site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep.</p><p>&nbsp;</p><p>In a clinical study in infants vaccinated at 2, 3, and 4&nbsp;months of age, fever &ge;&nbsp;38&deg;C was reported at higher rates among infants who received Prevenar&nbsp;(7‑valent) concomitantly with Infanrix hexa (28.3% to 42.3%) than in infants receiving Infanrix hexa alone (15.6% to 23.1%). After a booster dose at 12 to 15 months of age, fever &ge;&nbsp;38&deg;C was reported in 50.0% of infants who received Prevenar&nbsp;(7‑valent) and Infanrix hexa at the same time as compared to 33.6% of infants receiving Infanrix hexa alone. These reactions were mostly moderate (less than or equal to 39&deg;C) and transient.</p><p>&nbsp;</p><p>An increase in vaccination-site reactions was reported in children older than 12 months compared to rates observed in infants during the primary series with Prevenar&nbsp;13.</p><p>&nbsp;</p><p>Adverse reactions from clinical studies</p><p>In clinical studies, the safety profile of Prevenar&nbsp;13 was similar to Prevenar. The following frequencies are based on adverse reactions assessed in Prevenar&nbsp;13 clinical studies:</p><p>&nbsp;</p><p>Immune system disorders:</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reaction including face oedema, dyspnoea, bronchospasm</p><p>&nbsp;</p><p>Nervous system disorders:</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions (including febrile convulsions)</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotonic-hyporesponsive episode</p><p>&nbsp;</p><p>Gastrointestinal disorders:</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting; diarrhoea</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria or urticaria-like rash</p><p>&nbsp;</p><p>General disorders and administration site conditions:</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia; irritability; any vaccination-site erythema, induration/swelling or pain/tenderness; somnolence; poor quality sleep</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccination-site erythema or induration/swelling 2.5&nbsp;cm&ndash;7.0&nbsp;cm (after the booster dose and in older children [age 2 to 5 years])</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia &gt;&nbsp;39&deg;C; vaccination-site movement impairment (due to pain); vaccination‑site erythema or induration/swelling 2.5&nbsp;cm&ndash;7.0&nbsp;cm (after infant series)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccination-site erythema, induration/swelling &gt;&nbsp;7.0&nbsp;cm; crying</p><p>&nbsp;</p><p>Additional information in special populations:</p><p>Apnoea in very premature infants (&pound;&nbsp;28 weeks of gestation) (see section 4.4).</p><p>&nbsp;</p><p>Children and adolescents aged 6 to 17 years of age</p><p>Safety was evaluated in 592 children (294 children aged 5 to 10 years previously immunised with at least one dose of Prevenar and 298 children aged 10 to 17 years who had not received a pneumococcal vaccine).</p><p>&nbsp;</p><p>The most common adverse events in children and adolescents 6 to 17 years of age were:</p><p>&nbsp;</p><p>Nervous system disorders:</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches</p><p>&nbsp;</p><p>Gastrointestinal disorders:</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting; diarrhoea</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash; urticaria or urticaria-like rash</p><p>&nbsp;</p><p>General disorders and administration site conditions:</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability; any vaccination-site erythema; induration/swelling or pain/tenderness; somnolence; poor quality sleep;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaccination-site tenderness (including impaired movement)</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia</p><p>&nbsp;</p><p>Other adverse events previously observed in infants and children 6 weeks to 5 years of age may also be applicable to this age group but were not seen in this study possibly due to the small sample size.</p><p>&nbsp;</p><p>Additional information in special populations</p><p>Children and adolescents with sickle cell disease, HIV infection, or an haematopoietic stem cell transplant have similar frequencies of adverse reactions, except that headaches, vomiting, diarrhoea, pyrexia, fatigue, arthralgia, and myalgia were very common.</p><p>&nbsp;</p><p>Adults &ge;&nbsp;18 years and the elderly</p><p>Safety was assessed in 7 clinical studies including 91,593 adults ranging in age from 18 to 101&nbsp;years. Prevenar&nbsp;13 was administered to 48,806 adults; 2,616 (5.4%) aged 50 to 64 years, and 45,291 (92.8%) aged 65 years and older. One of the 7 studies included a group of adults (n=899) ranging from 18 to 49 years who received Prevenar&nbsp;13 and who were not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Of the Prevenar&nbsp;13 recipients 1,916&nbsp;adults were previously vaccinated with the 23‑valent pneumococcal polysaccharide vaccine at least 3&nbsp;years prior to study vaccination, and 46,890 were 23-valent pneumococcal polysaccharide vaccine unvaccinated.</p><p>&nbsp;</p><p>A trend to lower frequency of adverse reactions was associated with greater age; adults &gt;&nbsp;65&nbsp;years of age (regardless of prior pneumococcal vaccination status) reported fewer adverse reactions than younger adults, with adverse reactions generally most common in the youngest adults, 18 to 29&nbsp;years of age.</p><p>&nbsp;</p><p>Overall, the frequency categories were similar for all age groups, with the exception of vomiting which was very common (&sup3;&nbsp;1/10) in adults aged 18 to 49&nbsp;years and common (&sup3;&nbsp;1/100 to&nbsp;&lt;&nbsp;1/10) in all other age groups, and pyrexia was very common in adults aged 18 to 29&nbsp;years and common in all other age groups. Severe vaccination-site pain/tenderness and severe limitation of arm movement was very common in adults 18 to 39&nbsp;years and common in all other age groups.</p><p>&nbsp;</p><p>Adverse reactions from clinical studies</p><p>Local reactions and systemic events were solicited daily after each vaccination for 14 days in 6&nbsp;studies and 7 days in the remaining study. The following frequencies are based on adverse reactions assessed in Prevenar&nbsp;13 clinical studies in adults:</p><p><u>&nbsp;</u></p><p>Metabolism and nutrition disorders:</p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&nbsp;</p><p>Nervous system disorders:</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches</p><p>&nbsp;</p><p>Gastrointestinal disorders:</p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea; vomiting (in adults aged 18 to 49&nbsp;years)</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (in adults aged 50&nbsp;years and over)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&nbsp;</p><p>Immune system disorders:</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reaction including face oedema, dyspnoea, bronchospasm</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:</p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&nbsp;</p><p><u>General disorders and administration site conditions:</u></p><p>Very common<strong>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Chills; fatigue; vaccination-site erythema; vaccination-site induration/swelling; vaccination-site pain/tenderness (severe vaccination-site pain/tenderness very common in adults aged 18 to 39&nbsp;years); limitation of arm movement (severe limitation of arm movements very common in adults aged 18 to 39&nbsp;years)</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia (very common in adults aged 18 to 29&nbsp;years)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lymphadenopathy localized to the region of the vaccination-site</p><p><u>&nbsp;</u></p><p><u>Musculoskeletal and connective tissue disorders:</u></p><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia; myalgia</p><p>&nbsp;</p><p>Overall, no significant differences in frequencies of adverse reactions were seen when Prevenar&nbsp;13 was given to adults previously vaccinated with the pneumococcal polysaccharide vaccine.</p><p>&nbsp;</p><p><em>Additional information in special populations</em></p><p>Adults with HIV infection have similar frequencies of adverse reactions, except that pyrexia and vomiting were very common and nausea common.</p><p>&nbsp;</p><p>Adults with an haematopoietic stem cell transplant have similar frequencies of adverse reactions, except that pyrexia and vomiting were very common.</p><p>&nbsp;</p><p>Higher frequency in some solicited systemic reactions was observed when Prevenar&nbsp;13 was administered concomitantly with trivalent inactivated influenza vaccine (TIV) compared to TIV given alone (headache, chills, rash, decreased appetite, arthralgia, and myalgia) or Prevenar&nbsp;13 given alone (headache, fatigue, chills, decreased appetite, and arthralgia).</p><p>&nbsp;</p><p>Adverse reactions from Prevenar&nbsp;13 postmarketing experience</p><p>The following are considered adverse drug reactions for Prevenar&nbsp;13; because these reactions were derived from spontaneous reports, the frequencies could not be determined and are thus considered as not known.</p><p>&nbsp;</p><p>Blood and lymphatic system disorders:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lymphadenopathy (localised to the region of the vaccination-site)</p><p>&nbsp;</p><p>Immune system disorders:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic/anaphylactoid reaction including shock; angioedema</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythema multiforme</p><p>&nbsp;</p><p>General disorders and administration site conditions:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccination-site urticaria; vaccination-site dermatitis; vaccination-site pruritus; flushing</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance and Drug Safety Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with Prevenar&nbsp;13 is unlikely due to its presentation as a pre-filled syringe. However, in infants and children there have been reports of overdose with Prevenar&nbsp;13 defined as subsequent doses administered closer than recommended to the previous dose. In general, adverse events reported with overdose are consistent with those that have been reported with doses given in the recommended paediatric schedules of Prevenar&nbsp;13.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: vaccines, pneumococcal vaccines; ATC code: J07AL02</p><p>&nbsp;</p><p>Prevenar&nbsp;13 contains the 7 pneumococcal capsular polysaccharides that are in Prevenar (4, 6B, 9V, 14, 18C, 19F, 23F) plus 6 additional polysaccharides (1, 3, 5, 6A, 7F, 19A) all conjugated to CRM<sub>197</sub> carrier protein.</p><p>&nbsp;</p><p><u>Burden of disease</u></p><p>&nbsp;</p><p><em>Infants and children aged 6</em><em>&nbsp;</em><em>weeks to 5</em><em>&nbsp;</em><em>years</em></p><p>&nbsp;</p><p>Based on serotype surveillance in Europe performed before the introduction of Prevenar, Prevenar&nbsp;13 is estimated to cover 73-100% (depending on the country) of serotypes causing invasive pneumococcal disease (IPD) in children less than 5 years of age. In this age group, serotypes 1, 3, 5, 6A, 7F, and 19A account for 15.6% to 59.7% of invasive disease, depending on the country, the time period studied, and the use of Prevenar.</p><p>&nbsp;</p><p>Acute otitis media (AOM) is a common childhood disease with different aetiologies. Bacteria can be responsible for 60-70% of clinical episodes of AOM. <em>S. pneumoniae</em> is one of the most common causes of bacterial AOM worldwide.</p><p>&nbsp;</p><p>Prevenar&nbsp;13 is estimated to cover over 90% of serotypes causing antimicrobial-resistant IPD.</p><p>&nbsp;</p><p><em>Children and adolescents aged 6 to 17&nbsp;years</em></p><p>&nbsp;</p><p>In children and adolescents aged 6 to 17&nbsp;years, the incidence of pneumococcal disease is low, however, there is an increased risk of morbidity and mortality in those with underlying comorbidities.</p><p>&nbsp;</p><p><em>Adults </em><em>&ge;18 years and the elderly</em></p><p>&nbsp;</p><p>Pneumonia is the most common clinical presentation of pneumococcal disease in adults.</p><p><em>&nbsp;</em></p><p>The reported incidence of community-acquired pneumonia (CAP) and IPD in Europe varies by country, increases with age from 50 years and is highest in individuals aged &ge;&nbsp;65&nbsp;years. S.&nbsp;pneumoniae is the most frequent cause of CAP, and is estimated to be responsible for approximately 30% of all CAP cases requiring hospitalisation in adults in developed countries.</p><p>&nbsp;</p><p>Bacteraemic pneumonia (approximately 80% of IPD in adults), bacteraemia without a focus, and meningitis are the most common manifestations of IPD in adults. Based on surveillance data following the introduction of Prevenar but before the introduction of Prevenar&nbsp;13 in childhood vaccination programmes, the pneumococcal serotypes in Prevenar&nbsp;13 may be responsible for at least 50 &ndash; 76% (depending on country) of IPD in adults.</p><p>&nbsp;</p><p>The risk for CAP and IPD in adults also increases with chronic underlying medical conditions, specifically, anatomical or functional asplenia, diabetes mellitus, asthma, chronic cardiovascular, pulmonary, kidney or liver disease, and it is highest in those who are immune-suppressed such as those with malignant haematological diseases or HIV infection.</p><p>&nbsp;</p><p>Prevenar&nbsp;13 immunogenicity clinical studies in infants, children and adolescents</p><p>&nbsp;</p><p>The protective efficacy of Prevenar&nbsp;13 against IPD has not been studied. As recommended by the World Health Organization (WHO) the assessment of potential efficacy against IPD in infants and young children has been based on a comparison of immune responses to the seven common serotypes shared between Prevenar&nbsp;13 and Prevenar, for which protective efficacy has been proven (for Prevenar (7-valent) efficacy in infants and children, see below). Immune responses to the additional 6&nbsp;serotypes were also measured.</p><p>&nbsp;</p><p>Immune responses following a three-dose primary infant series</p><p>&nbsp;</p><p>Clinical studies have been conducted in a number of European countries and the US using a range of vaccination schedules, including two randomised non-inferiority studies (Germany using a 2, 3, 4&nbsp;month primary series [006] and US using a 2, 4, 6&nbsp;month primary series [004]). In these two studies pneumococcal immune responses were compared using a set of non-inferiority criteria including the percentage of subjects with serum anti-polysaccharide serotype-specific IgG &ge;&nbsp;0.35&nbsp;&mu;g/ml one month after the primary series and the comparison of IgG geometric mean concentrations (ELISA GMCs); in addition, functional antibody titres (OPA) between subjects receiving Prevenar&nbsp;13 and Prevenar were compared. For the six additional serotypes, these values were compared with the lowest response among all of the seven common serotypes in the Prevenar recipients.</p><p>&nbsp;</p><p>The non-inferiority immune response comparisons for study 006, based on the proportion of infants achieving anti-polysaccharide IgG concentrations &ge;&nbsp;0.35&nbsp;&mu;g/ml, are shown in Table 1. Results for study 004 were similar. Prevenar&nbsp;13 non-inferiority (lower bound of the 95% CI for the difference in percentage of responders at 0.35&nbsp;&micro;g/ml between groups was &gt;-10%) was demonstrated for all 7&nbsp;common serotypes, except for serotype 6B in study 006 and serotypes 6B and 9V in study 004, which missed by a small margin. All seven common serotypes met pre-defined non-inferiority criteria for IgG ELISA GMCs. Prevenar&nbsp;13 elicited comparable, although slightly lower, antibody levels than Prevenar for the 7 common serotypes. The clinical relevance of these differences is not known.</p><p>&nbsp;</p><p>Non-inferiority was met for the 6 additional serotypes based on the proportion of infants achieving antibody concentrations &ge;&nbsp;0.35&nbsp;&mu;g/ml and comparison of IgG ELISA GMCs in study 006 and was met for 5 out of the 6 serotypes, with the exception of serotype 3 for study 004. For serotype 3, the percentages of Prevenar&nbsp;13 recipients with serum IgG &ge;&nbsp;0.35&nbsp;&mu;g/ml were 98.2% (study 006) and 63.5% (study 004).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="4"><p><strong>Table 1: Comparison of the proportion of subjects achieving a pneumococcal anti</strong>‑<strong>polysaccharide IgG antibody concentration &ge;&nbsp;0.35&nbsp;&mu;g/ml after dose 3 of the infant series &ndash; study 006</strong></p></td></tr><tr><td><p><strong>Serotypes</strong></p></td><td><p><strong>Prevenar&nbsp;13 </strong></p><p><strong>%</strong></p><p><strong>(N=282-285)</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>7-valent Prevenar</strong></p><p><strong>%</strong></p><p><strong>(N=277-279)</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>Difference<br />(95&nbsp;% CI)</strong></p></td></tr></thead><tbody><tr><td colspan="4"><p><strong>7-valent Prevenar serotypes</strong></p></td></tr><tr><td><p>4</p></td><td><p>98.2</p></td><td><p>98.2</p></td><td><p>0.0 (-2.5, 2.6)</p></td></tr><tr><td><p>6B</p></td><td><p>77.5</p></td><td><p>87.1</p></td><td><p>-9.6 (-16.0, -3.3)</p></td></tr><tr><td><p>9V</p></td><td><p>98.6</p></td><td><p>96.4</p></td><td><p>2.2 (-0.4, 5.2)</p></td></tr><tr><td><p>14</p></td><td><p>98.9</p></td><td><p>97.5</p></td><td><p>1.5 (-0.9, 4.1)</p></td></tr><tr><td><p>18C</p></td><td><p>97.2</p></td><td><p>98.6</p></td><td><p>-1.4 (-4.2, 1.2)</p></td></tr><tr><td><p>19F</p></td><td><p>95.8</p></td><td><p>96.0</p></td><td><p>-0.3 (-3.8, 3.3)</p></td></tr><tr><td><p>23F</p></td><td><p>88.7</p></td><td><p>89.5</p></td><td><p>-0.8 (-6.0, 4.5)</p></td></tr><tr><td colspan="4"><p><strong>Additional serotypes in Prevenar&nbsp;13</strong></p></td></tr><tr><td><p>1</p></td><td><p>96.1</p></td><td><p>87.1*</p></td><td><p>9.1 (4.5, 13.9)</p></td></tr><tr><td><p>3</p></td><td><p>98.2</p></td><td><p>87.1</p></td><td><p>11.2 (7.0, 15.8)</p></td></tr><tr><td><p>5</p></td><td><p>93.0</p></td><td><p>87.1</p></td><td><p>5.9 (0.8, 11.1)</p></td></tr><tr><td><p>6A</p></td><td><p>91.9</p></td><td><p>87.1</p></td><td><p>4.8 (-0.3, 10.1)</p></td></tr><tr><td><p>7F</p></td><td><p>98.6</p></td><td><p>87.1</p></td><td><p>11.5 (7.4, 16.1)</p></td></tr><tr><td><p>19A</p></td><td><p>99.3</p></td><td><p>87.1</p></td><td><p>12.2 (8.3, 16.8)</p></td></tr><tr><td colspan="4"><p><sup>* </sup>The serotype in Prevenar with the lowest percent response rate was 6B in study 006 (87.1&nbsp;%).</p></td></tr></tbody></table><p>&nbsp;</p><p>Prevenar&nbsp;13 elicited functional antibodies to all 13 vaccine serotypes in studies 004 and 006. For the 7&nbsp;common serotypes there were no differences between groups in the proportion of subjects with OPA titres &ge;&nbsp;1:8. For each of the seven common serotypes, &gt;&nbsp;96% and &gt;90&nbsp;% of the Prevenar&nbsp;13 recipients reached an OPA titre &ge;&nbsp;1:8 one month after the primary series in studies 006 and 004, respectively.</p><p>&nbsp;</p><p>For each of the 6 additional serotypes, Prevenar&nbsp;13 elicited OPA titres &ge;&nbsp;1:8 in 91.4% to 100% of vaccinees one month after the primary series in studies 004/006. The functional antibody (OPA) geometric mean titres for serotypes 1, 3 and 5 were lower than the titres for each of the other additional serotypes; the clinical relevance of this observation for protective efficacy is unknown.</p><p>&nbsp;</p><p>Immune responses following a two-dose primary infant series</p><p>&nbsp;</p><p>The immunogenicity after two doses in infants has been documented in four studies. The proportion of infants achieving a pneumococcal anti-capsular polysaccharide IgG concentration &ge;&nbsp;0.35&nbsp;mg/ml one month after the second dose ranged from 79.6% to 98.5% across 11 of the 13 vaccine serotypes. Smaller proportions of infants achieved this antibody concentration threshold for serotype 6B (27.9% to 57.3%) and 23F (55.8% to 68.1%) for all studies using a 2, 4&nbsp;month regimen, compared to 58.4% for serotype 6B and 68.6% for 23F for a study using a 3, 5&nbsp;month regimen. After the booster dose, all vaccine serotypes including 6B and 23F had immune responses consistent with adequate priming with a two-dose primary series. In a UK study, the functional antibody (OPA) responses were comparable for all serotypes including 6B and 23F in the Prevenar and Prevenar&nbsp;13 arms after the primary series at two and four months of age and after the booster dose at 12 months of age. For Prevenar&nbsp;13 recipients, the proportion of responders with an OPA titre &sup3;&nbsp;1:8 was at least 87&nbsp;% following the infant series, and at least 93% following the booster dose. The OPA geometric mean titres for serotypes 1, 3 and 5 were lower than the titres for each of the other additional serotypes; the clinical relevance of this observation is unknown.</p><p>&nbsp;</p><p>Booster responses following two-dose and three-dose primary infant series</p><p>&nbsp;</p><p>Following the booster dose, antibody concentrations increased from the pre-booster level for all 13 serotypes. Post-booster antibody concentrations were higher for 12 serotypes than those achieved after the infant primary series. These observations are consistent with adequate priming (the induction of immunologic memory). The immune response for serotype 3 following the booster dose was not increased above the levels seen after the infant vaccination series; the&nbsp;clinical relevance of this observation regarding the induction of serotype 3 immune memory is unknown.</p><p>&nbsp;</p><p>Antibody responses to booster doses following two‑dose or three-dose infant primary series were comparable for all 13 vaccine serotypes.</p><p>&nbsp;</p><p><strong>For children aged from 7&nbsp;months to 5&nbsp;years, age appropriate catch-up immunisation schedules (as described in section 4.2) result in levels of anti-capsular polysaccharide IgG antibody responses to each of the 13 serotypes that are at least comparable to those of a three-dose primary series in infants.</strong></p><p><strong>&nbsp;</strong></p><p>Antibody persistence and immunological memory were evaluated in a study in healthy children who received a single dose of Prevenar&nbsp;13 at least 2&nbsp;years after they had been previously immunised with either 4 doses of Prevenar, a 3-dose infant series of Prevenar followed by Prevenar&nbsp;13 at 12 months of age, or 4 doses of Prevenar&nbsp;13.</p><p>&nbsp;</p><p>The single dose of Prevenar&nbsp;13, in children approximately 3.4 years of age regardless of previous vaccination history with Prevenar or Prevenar&nbsp;13, induced a robust antibody response for both the 7&nbsp;common serotypes and the 6 additional serotypes in Prevenar&nbsp;13.</p><p>&nbsp;</p><p>Since the introduction of 7-valent Prevenar in 2000, pneumococcal disease surveillance data have not shown that the immunity elicited by Prevenar in infancy has waned over time.</p><p>&nbsp;</p><p><u>Preterm Infants</u></p><p><u>&nbsp;</u></p><p>Safety and immunogenicity of Prevenar&nbsp;13 given at 2, 3, 4 and 12 months was assessed in approximately 100 prematurely born infants (mean Estimated Gestational Age [EGA], 31 weeks; range, 26 to 36 weeks) and compared with approximately 100 infants born at term (mean EGA, 39&nbsp;weeks; range, 37 to 42 weeks).</p><p>&nbsp;</p><p>Immune responses in preterm and term infants were compared using the proportion of subjects achieving a pneumococcal polysaccharide IgG binding antibody concentration &ge;0.35&nbsp;&mu;g/mL 1&nbsp;month after the infant series, the approach used for immunogenicity comparisons of Prevenar&nbsp;13 to Prevenar based on WHO guidelines.</p><p>&nbsp;</p><p>More than 85% achieved a pneumococcal polysaccharide IgG binding antibody concentration &ge;0.35&nbsp;&micro;g/mL 1&nbsp;month after the infant series, except for serotypes 5&nbsp;(71.7%), 6A (82.7%), and 6B (72.7%) in the preterm group. For these 3 serotypes, the proportion of responders among preterm infants was significantly lower than among term infants. Approximately one month after the toddler dose, the proportion of subjects in each group achieving this same antibody concentration threshold was &gt;97%, except for serotype 3 (71% in preterm infants and 79% in term infants). It is unknown whether immunological memory to all serotypes is induced in pre-term infants. In general, serotype‑specific IgG GMCs were lower for preterm infants than term infants.</p><p>&nbsp;</p><p>After the infant series, OPA GMTs were similar in preterm infants compared to term infants except for serotype 5, which was lower in preterm infants. OPA GMTs after the toddler dose relative to those after the infant series were similar or lower for 4 serotypes (4, 14, 18C, and 19F) and were statistically significantly higher for 6 of 13 serotypes (1, 3, 5, 7F, 9V, and 19A) in preterm infants compared to 10 of 13 serotypes (1, 3, 4, 5, 6A, 7F, 9V, 18C,&nbsp;19A, and 23F) in term infants.</p><p>&nbsp;</p><p><u>Children (12-59 months) completely immunised with Prevenar (7-valent)</u></p><p><u>&nbsp;</u></p><p>Following administration of a single dose of Prevenar&nbsp;13 to children (12-59 months) who are considered completely immunised with Prevenar (7-valent) (either 2 or 3 dose primary series plus booster), the proportion achieving serum IgG levels &ge;0.35&nbsp;&micro;g/ml and OPA titres &ge;1:8 was at least 90%. However, 3 (serotypes 1, 5 and 6A) of the 6 additional serotypes showed lower IgG GMC and OPA GMT when compared with children who had received at least one previous vaccination with Prevenar&nbsp;13. The clinical relevance of the lower GMCs and GMTs is currently unknown.</p><p><em><u>&nbsp;</u></em></p><p><u>Unvaccinated Children (12-23 months)</u></p><p><u>&nbsp;</u></p><p>Studies in unvaccinated children (12‑23 months) with Prevenar (7-valent) demonstrated that 2&nbsp;doses were required to achieve serum IgG concentrations for 6B and 23F similar to those induced by a 3‑dose infant series.</p><p>&nbsp;</p><p><u>Children and Adolescents 5 to 17 years of age<strong> </strong></u></p><p>&nbsp;</p><p>In an open-label study in 592 healthy children and adolescents including those with asthma (17.4%) who may be predisposed to pneumococcal infection, Prevenar&nbsp;13 elicited immune responses to all 13&nbsp;serotypes. A single dose of Prevenar&nbsp;13 was given to children 5 to 10 years of age previously vaccinated with at least 1 dose of Prevenar, and children and adolescents 10 to 17 years of age who had never received a pneumococcal vaccine.</p><p>&nbsp;</p><p>In both the children 5 to 10&nbsp;years of age and children and adolescents aged 10 to 17&nbsp;years, the immune response to Prevenar&nbsp;13 was non inferior to Prevenar for the 7 common serotypes and to Prevenar&nbsp;13 for the 6 additional serotypes compared to the immune response after the fourth dose in infants vaccinated at 2, 4, 6 and 12-15&nbsp;months of age as measured by serum IgG.</p><p>&nbsp;</p><p>In children and adolescents aged 10 to 17&nbsp;years of age OPA GMTs 1&nbsp;month after vaccination were noninferior to OPA GMTs in the 5 to 10&nbsp;year old age group for 12 of the 13&nbsp;serotypes (except serotype&nbsp;3).</p><p>&nbsp;</p><p><u>Immune responses after subcutaneous administration</u></p><p>&nbsp;</p><p>Subcutaneous administration of Prevenar&nbsp;13 was evaluated in a non-comparative study in 185 healthy Japanese infants and children who received 4 doses at 2, 4, 6 and 12-15&nbsp;months of age. The study demonstrated that safety and immunogenicity were generally comparable with observations made in studies of intramuscular administration.</p><p>&nbsp;</p><p><u>Prevenar&nbsp;13 Effectiveness</u></p><p>&nbsp;</p><p><em>Invasive Pneumococcal Disease</em></p><p>Data published by Public Health England showed that, four years after the introduction of Prevenar as a two dose primary infant series with booster dose in the second year of life and with a 94% vaccine uptake, there was a 98% (95% CI 95; 99) reduction in disease caused by the 7 vaccine serotypes in England and Wales. Subsequently, four years following the switch to Prevenar&nbsp;13, the additional reduction in incidence of IPD due to the 7&nbsp;serotypes in Prevenar ranged from 76% in children less than 2&nbsp;years of age to 91% in children 5‑14&nbsp;years of age. The serotype specific reductions for each of the 5 additional serotypes in Prevenar&nbsp;13 (no cases of serotype 5 IPD were observed) by age group are shown in Table 2 and ranged from 68% (serotype 3) to 100% (serotype 6A) for children less than 5&nbsp;years of age. Significant incidence reductions were also observed in older age groups who had not been vaccinated with Prevenar&nbsp;13 (indirect effect).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:595px"><tbody><tr><td colspan="12" style="vertical-align:top"><p><strong>Table 2: Serotype specific number of cases and incidence reductions of IPD in 2013/14 compared to 2008/09‑2009/10 (2008/10) by age in England and Wales</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>&lt;5&nbsp;years of age</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>5 to 64&nbsp;years of age</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>&ge;65&nbsp;years of age</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>2008-10<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>2013/14<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>% Incidence reduction (95% CI*)</p></td><td style="vertical-align:top"><p>2008-10<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>2013/14<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>% Incidence reduction (95% CI*)</p></td><td style="vertical-align:top"><p>2008-10<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>2013/14<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>% Incidence reduction (95% CI*)</p></td></tr><tr><td colspan="12" style="vertical-align:top"><p><strong>Additional serotypes covered by Prevenar&nbsp;13</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1</strong></p></td><td style="vertical-align:top"><p>59 (54)</p></td><td style="vertical-align:top"><p>5 (5)</p></td><td style="vertical-align:top"><p>91%</p><p>(98%; 68%)**</p></td><td colspan="3" style="vertical-align:top"><p>458 (382)</p></td><td style="vertical-align:top"><p>77 (71)</p></td><td style="vertical-align:top"><p>83%</p><p>(88%; 74%)**</p></td><td style="vertical-align:top"><p>102 (89)</p></td><td style="vertical-align:top"><p>13 (13)</p></td><td style="vertical-align:top"><p>87%</p><p>(94%; 72%)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>3</strong></p></td><td style="vertical-align:top"><p>26 (24)</p></td><td style="vertical-align:top"><p>8 (8)</p></td><td style="vertical-align:top"><p>68%</p><p>(89%; 6%)</p></td><td colspan="3" style="vertical-align:top"><p>178 (148)</p></td><td style="vertical-align:top"><p>73 (68)</p></td><td style="vertical-align:top"><p>59%</p><p>(72%; 38%)**</p></td><td style="vertical-align:top"><p>256 (224)</p></td><td style="vertical-align:top"><p>143 (146)</p></td><td style="vertical-align:top"><p>44%</p><p>(57%; 27%)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>6A</strong></p></td><td style="vertical-align:top"><p>10 (9)</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>100%</p><p>(100%; 62%)**</p></td><td colspan="3" style="vertical-align:top"><p>53 (44)</p></td><td style="vertical-align:top"><p>5 (5)</p></td><td style="vertical-align:top"><p>90%</p><p>(97%; 56%)**</p></td><td style="vertical-align:top"><p>94 (82)</p></td><td style="vertical-align:top"><p>5 (5)</p></td><td style="vertical-align:top"><p>95%</p><p>(99%; 81%)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>7F</strong></p></td><td style="vertical-align:top"><p>90 (82)</p></td><td style="vertical-align:top"><p>8 (8)</p></td><td style="vertical-align:top"><p>91%</p><p>(97%; 74%)**</p></td><td colspan="3" style="vertical-align:top"><p>430 (361)</p></td><td style="vertical-align:top"><p>160 (148)</p></td><td style="vertical-align:top"><p>63%</p><p>(71%; 50%)**</p></td><td style="vertical-align:top"><p>173 (152)</p></td><td style="vertical-align:top"><p>75 (77)</p></td><td style="vertical-align:top"><p>56%</p><p>(70%; 37%)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>19A</strong></p></td><td style="vertical-align:top"><p>85 (77)</p></td><td style="vertical-align:top"><p>7 (7)</p></td><td style="vertical-align:top"><p>91%</p><p>(97%; 75%)**</p></td><td colspan="3" style="vertical-align:top"><p>225 (191)</p></td><td style="vertical-align:top"><p>104 (97)</p></td><td style="vertical-align:top"><p>54%</p><p>(65%; 32%)**</p></td><td style="vertical-align:top"><p>279 (246)</p></td><td style="vertical-align:top"><p>97 (99)</p></td><td style="vertical-align:top"><p>65%</p><p>(75%; 53%)**</p></td></tr><tr><td colspan="12" style="vertical-align:top"><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corrected for proportion of samples serotyped, missing age, denominator compared with 2009/10, and for the trend in total invasive pneumococcal disease up to 2009/10 (after which no trend correction was applied).</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; 95% CI inflated from a Poisson interval based on over-dispersion of 2.1 seen from modelling of 2000‑06&nbsp;pre‑Prevenar all IPD data.</p><p>**&nbsp;&nbsp; p&lt;0.005 to cover 6A where p=0.002</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Otitis media (OM)</em></p><p>In a published study performed in Israel, using a 2-dose primary series plus booster dose in the second year of life, the impact of Prevenar&nbsp;13 on OM was documented in a population‑based active‑surveillance system with tympanocentesis culturing of middle ear fluid in Israeli children less than 2&nbsp;years of age with OM.</p><p>&nbsp;</p><p>Following the introduction of Prevenar and subsequently Prevenar&nbsp;13 there was a decline in incidence from 2.1 to 0.1 cases per 1000 children (95%) for the Prevenar serotypes plus serotype 6A and a decline in incidence from 0.9 to 0.1 cases per 1000 children (89%) for the additional serotypes 1, 3, 5, 7F, and 19A in Prevenar&nbsp;13. The annual overall pneumococcal incidence of OM declined from 9.6 to 2.1 cases per 1000 children (78%) between July 2004 (prior to the introduction of Prevenar) and June 2013 (post Prevenar&nbsp;13 introduction).</p><p>&nbsp;</p><p><em>Pneumonia</em></p><p>In a multicenter observational study in France comparing the periods before and after the switch from Prevenar to Prevenar&nbsp;13, there was 16% (2060 to 1725 cases) reduction in all community acquired pneumonia (CAP) cases in emergency departments in children 1&nbsp;month to 15&nbsp;years of age. Reductions were 53% (167 to 79 cases) (p&lt;0.001) for CAP cases with pleural effusion and 63% (64 to 24 cases) (p&lt;0.001) for microbiologically confirmed pneumococcal CAP cases. In the second year after the introduction of Prevenar&nbsp;13 the total number of CAP cases due to the 6 additional vaccine serotypes in Prevenar&nbsp;13 was reduced from 27 to 7&nbsp;isolates (74%).</p><p>&nbsp;</p><p>The decrease in all cause pneumonia cases was most pronounced in the younger vaccinated age groups with a decrease of 31.8% (757 to 516 cases) and 16.6% (833 to 695 cases) in the age groups &lt;2 years and 2 to 5 years, respectively. The incidence in older, predominantly non-vaccinated children (&gt;5 years) did not change over the duration of the study.</p><p>&nbsp;</p><p>&nbsp;&nbsp;In an ongoing surveillance system (2004 to 2013) to document the impact of Prevenar and subsequently Prevenar&nbsp;13 on CAP in children less than 5&nbsp;years in Southern Israel using a 2&nbsp;dose primary series with a booster dose in the second year of life, there was a reduction of 68% (95%&nbsp;CI&nbsp;73; 61) in outpatient visits and 32% (95% CI 39; 22) in hospitalizations for alveolar CAP following the introduction of Prevenar&nbsp;13 when compared to the period before the introduction of Prevenar.</p><p>&nbsp;</p><p>Effect on nasopharyngeal carriage</p><p>&nbsp;</p><p>In a surveillance study in France in children presenting with acute otitis media, changes in nasopharyngeal (NP) carriage of pneumococcal serotypes were evaluated following the introduction of Prevenar (7-valent) and subsequently Prevenar&nbsp;13. Prevenar&nbsp;13 significantly reduced NP carriage of the 6 additional serotypes (and serotype 6C) combined and individual serotypes 6C, 7F, 19A when compared with Prevenar. A reduction in carriage was also seen for serotype 3 (2.5% vs 1.1%; p=0.1). There was no carriage of serotypes 1 and 5 observed.</p><p>&nbsp;</p><p>The effect of pneumococcal conjugate vaccination on nasopharyngeal carriage was studied in a randomised double-blind study in which infants received either Prevenar&nbsp;13 or Prevenar (7-valent) at 2, 4, 6 and 12 months of age in Israel. Prevenar&nbsp;13 significantly reduced newly identified NP acquisition of the 6 additional serotypes (and serotype 6C) combined and of individual serotypes 1, 6A, 6C, 7F, 19A when compared with Prevenar. There was no reduction seen in serotype 3 and for serotype 5 the colonization was too infrequent to assess impact. For 6 of the remaining 7 common serotypes, similar rates of NP acquisition were observed in both vaccine groups; for serotype 19F a significant reduction was observed.</p><p>&nbsp;</p><p>In this study, reductions of <em>S. pneumoniae</em> serotypes 19A, 19F, and 6A not susceptible to a number of antibiotics were documented. The reductions ranged between 34% and 62% depending on serotype and antibiotic.</p><p>&nbsp;</p><p>Prevenar (7-valent vaccine) protective efficacy in infants and children</p><p>&nbsp;</p><p>The efficacy of 7-valent<strong> </strong>Prevenar was evaluated in two major studies &ndash; the Northern California Kaiser Permanente (NCKP) study and the Finnish Otitis Media (FinOM) study. Both studies were randomised, double-blind, active-control studies in which infants were randomised to receive either Prevenar or control vaccine (NCKP, meningococcal serogroup C CRM-conjugate [MnCC] vaccine; FinOM, hepatitis B vaccine) in a four-dose series at 2, 4, 6, and 12‑15 months of age. The efficacy results from these studies (for invasive pneumococcal disease, pneumonia, and acute otitis media) are presented below (Table 3).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td colspan="4"><p><strong>Table 3: Summary of efficacy of 7-valent Prevenar</strong><sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Test</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>VE</strong><sup>2</sup></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>NCKP: Vaccine-serotype IPD<sup>3</sup></p></td><td><p>30,258</p></td><td style="vertical-align:top"><p>97%</p></td><td style="vertical-align:top"><p>85, 100</p></td></tr><tr><td style="vertical-align:top"><p>NCKP: Clinical pneumonia with abnormal chest X-ray</p></td><td style="vertical-align:top"><p>23,746</p></td><td style="vertical-align:top"><p>35%</p></td><td style="vertical-align:top"><p>4, 56</p></td></tr><tr><td style="vertical-align:top"><p>NCKP: Acute Otitis Media (AOM)<sup>4</sup></p></td><td style="vertical-align:top"><p>23,746</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Total episodes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>4, 10</p></td></tr><tr><td style="vertical-align:top"><p>Recurrent AOM (3 episodes in 6 months, or 4 episodes in 1 year)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>3, 15</p></td></tr><tr><td style="vertical-align:top"><p>Recurrent AOM (5 episodes in 6 months, or 6 episodes in 1 year)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>23%</p></td><td style="vertical-align:top"><p>7, 36</p></td></tr><tr><td style="vertical-align:top"><p>Tympanostomy tube placement</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>2, 35</p></td></tr><tr><td style="vertical-align:top"><p>FinOM: AOM</p></td><td style="vertical-align:top"><p>1,662</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Total episodes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>-4, 16</p></td></tr><tr><td style="vertical-align:top"><p>All pneumococcal AOM</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>21, 45</p></td></tr><tr><td style="vertical-align:top"><p>Vaccine-serotype AOM</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>57%</p></td><td style="vertical-align:top"><p>44, 67</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>1</sup>Per protocol</p><p><sup>2</sup>Vaccine efficacy</p><p><sup>3</sup>October 1995 to April 20, 1999</p><p><sup>4</sup>October 1995 to April 30, 1998</p></td></tr></tbody></table><p>&nbsp;</p><p>Prevenar (7-valent) effectiveness</p><p>&nbsp;</p><p>The effectiveness (both direct and indirect effect) of 7-valent<strong> </strong>Prevenar against pneumococcal disease has been evaluated&nbsp;in both three-dose and two-dose primary infant series immunisation programmes, each with booster doses (Table 4). Following the widespread use of Prevenar, the incidence of IPD has been consistently and substantially reduced.</p><p>&nbsp;</p><p>Using the screening method, serotype-specific effectiveness estimates for 2 doses under the age of 1&nbsp;year in the UK were 66&nbsp;% (-29, 91&nbsp;%)&nbsp;and 100&nbsp;% (25, 100&nbsp;%) for serotype 6B and 23F, respectively.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 4: Summary of effectiveness of 7-valent Prevenar for invasive pneumococcal disease</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Country</strong></p><p><strong>(year of introduction)</strong></p></td><td style="vertical-align:top"><p><strong>Recommended schedule</strong></p></td><td style="vertical-align:top"><p><strong>Disease reduction, %</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr><tr><td style="vertical-align:top"><p>UK (England &amp; Wales)<sup>1 </sup>(2006)</p></td><td style="vertical-align:top"><p>2, 4, + 13 months</p></td><td style="vertical-align:top"><p><u>Vaccine serotypes</u>:</p><p>Two doses under age 1: 85%</p></td><td style="vertical-align:top"><p>49, 95%</p></td></tr><tr><td style="vertical-align:top"><p>USA (2000)</p><p>&nbsp;</p><p>Children &lt;&nbsp;5<sup>2</sup></p><p><sup>&nbsp;</sup></p><p>&nbsp;</p><p>Persons &ge;&nbsp;65<sup>3</sup></p></td><td style="vertical-align:top"><p>2, 4, 6, + 12-15 months</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Vaccine serotypes: 98%</p><p>All serotypes: 77%</p><p>&nbsp;</p><p>Vaccine serotypes: 76%</p><p>All serotypes: 38%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>97, 99%</p><p>73, 79%</p><p>&nbsp;</p><p>NA</p><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Canada (Quebec)<sup>4</sup></p><p>(2004)</p></td><td style="vertical-align:top"><p>2, 4, + 12 months</p></td><td style="vertical-align:top"><p>All serotypes: 73%</p><p><u>Vaccine serotypes</u>:</p><p>2-dose infant series: 99%</p><p>Completed schedule:100%</p></td><td style="vertical-align:top"><p>NA</p><p>&nbsp;</p><p>92, 100%</p><p>82, 100%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>1</sup>Children &lt;&nbsp;2 years of age. Calculated vaccine effectiveness as of June 2008 (Broome method).</p><p><sup>2</sup>2005 data.</p><p><sup>3</sup>2004 data.</p><p><sup>4</sup>Children &lt;&nbsp;5 years of age. January 2005 to December 2007. Complete effectiveness for routine 2+1 schedule not yet available.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Acute Otitis Media</em></p><p>Effectiveness of Prevenar in a 3+1 schedule has also been observed against acute otitis media and pneumonia since its introduction in a national immunisation programme. In a retrospective evaluation of a large US insurance database, AOM visits were reduced by 42.7&nbsp;% (95&nbsp;% CI, 42.4-43.1&nbsp;%), and prescriptions for AOM by 41.9&nbsp;% in children younger than 2 years of age, compared with a pre‑licensure baseline (2004 vs. 1997‑99). In a similar analysis, hospitalisations and ambulatory visits for all-cause pneumonia were reduced by 52.4&nbsp;% and 41.1&nbsp;%, respectively. For those events specifically identified as pneumococcal pneumonia, the observed reductions in hospitalisations and ambulatory visits were 57.6&nbsp;% and 46.9&nbsp;%, respectively, in children younger than 2 years of age, compared with a pre-licensure baseline (2004 vs. 1997‑99). While direct cause-and-effect cannot be inferred from observational analyses of this type, these findings suggest that Prevenar plays an important role in reducing the burden of mucosal disease (AOM and pneumonia) in the target population.</p><p><em>&nbsp;</em></p><p><u>Efficacy study in adults 65 years and older</u></p><p><em><u>&nbsp;</u></em></p><p>Efficacy against vaccine-type (VT) pneumococcal CAP and IPD was assessed in a large-scale randomised double-blind, placebo-controlled study (Community-Acquired Pneumonia Immunization Trial in Adults&ndash;CAPiTA) in the Netherlands. 84,496 subjects, 65 years and older received a single vaccination of either Prevenar&nbsp;13 or placebo in a 1:1 randomisation.</p><p>&nbsp;</p><p>The CAPiTA study enrolled volunteers &ge; 65 years of age whose demographic and health characteristics may differ from those seeking vaccination.</p><p>&nbsp;</p><p>A first episode of hospitalised, chest X‑ray confirmed pneumonia was identified in about 2% of this population (n=1,814 subjects) of which 329 cases were confirmed pneumococcal CAP and 182 cases were VT&nbsp;pneumococcal CAP in the per protocol and modified intent to treat (mITT) populations.</p><p>&nbsp;</p><p>Efficacy was &nbsp;demonstrated for the primary and &nbsp;secondary endpoints in the per protocol population. (Table 5).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 5: Vaccine efficacy (VE) for the primary and secondary endpoints of the CAPiTA study (per protocol population)</strong></p></td></tr><tr><td rowspan="2"><p><strong>Efficacy endpoint</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Cases</strong></p></td><td rowspan="2"><p><strong>VE (%)</strong></p><p><strong>(95.2% CI)</strong></p></td><td rowspan="2"><p><strong>p-value</strong></p></td></tr><tr><td><p><strong>Total</strong></p></td><td><p><strong>Prevenar 13 group</strong></p></td><td><p><strong>Placebo group</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Primary endpoint</em></p></td></tr><tr><td><p><strong>First episode of confirmed VT pneumococcal CAP</strong></p></td><td><p>139</p></td><td><p>49</p></td><td><p>90</p></td><td><p>45.56</p><p>(21.82, 62.49)</p></td><td><p>0.0006</p></td></tr><tr><td colspan="6"><p><em>Secondary endpoints</em></p></td></tr><tr><td><p><strong>First episode of confirmed NB/NI</strong><strong><sup>1</sup></strong><strong> vaccine type pneumococcal CAP</strong></p></td><td><p>93</p></td><td><p>33</p></td><td><p>60</p></td><td><p>45.00</p><p>(14.21, 65.31)</p></td><td><p>0.0067</p></td></tr><tr><td><p><strong>First episode of VT-IPD</strong><strong><sup>2</sup></strong></p></td><td><p>35</p></td><td><p>7</p></td><td><p>28</p></td><td><p>75.00</p><p>(41.06, 90.87)</p></td><td><p>0.0005</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1</sup>NB/NI &ndash; non-bacteraemic/non-invasive</p><p><sup>2</sup>VT-IPD &ndash; vaccine-type invasive pneumococcal disease</p></td></tr></tbody></table><p>&nbsp;</p><p>The duration of protective efficacy against a first episode of VT pneumococcal CAP, NB/NI&nbsp;VT&nbsp;pneumococcal CAP, and VT-IPD extended throughout the 4-year study.</p><p>&nbsp;</p><p>The study was not designed to demonstrate efficacy in subgroups, and the number of subjects &ge;&nbsp;85&nbsp;years of age was not sufficient to demonstrate efficacy in this age group.</p><p>&nbsp;</p><p>A <em>post-hoc</em> analysis was used to estimate the following public health outcomes against clinical CAP (as defined in the CAPiTA study, and based on clinical findings regardless of radiologic infiltrate or etiologic confirmation): vaccine efficacy (VE), incidence rate reduction (IRR), and number needed to vaccinate (NNV) (Table 6).</p><p>&nbsp;</p><p>IRR, also referred to as vaccine preventable disease incidence, is the number of cases of vaccine preventable disease per 100,000 person-years of observation.</p><p>&nbsp;</p><p>In Table 6, NNV is a measure that quantifies the number of people that need to be vaccinated in order to prevent one clinical CAP case.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:622px"><tbody><tr><td colspan="8" style="vertical-align:top"><p><strong>Table 6: Vaccine efficacy (VE) against clinical CAP<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Episodes</strong></p></td><td style="vertical-align:top"><p><strong>Vaccine efficacy<sup>1</sup> % (95% CI)</strong></p><p><strong>(1-sided p-value)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Incidence per 100,000 person-years of observation (PYO)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Incidence rate reduction</strong><strong><sup>2</sup></strong><strong> (95% CI)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Number needed to vaccinate</strong><strong><sup>3</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Prevenar 13</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Prevenar 13</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p>All episodes analysis</p></td><td style="vertical-align:top"><p>1375</p></td><td style="vertical-align:top"><p>1495</p></td><td style="vertical-align:top"><p>8.1</p><p>(-0.6, 16.1)</p><p>(0.034)</p></td><td style="vertical-align:top"><p>819.1</p></td><td style="vertical-align:top"><p>891.2</p></td><td style="vertical-align:top"><p>72.2</p><p>(-5.3, 149.6)</p></td><td style="vertical-align:top"><p>277</p></td></tr><tr><td style="vertical-align:top"><p>First episode analysis</p></td><td style="vertical-align:top"><p>1126</p></td><td style="vertical-align:top"><p>1214</p></td><td style="vertical-align:top"><p>7.3</p><p>(-0.4, 14.4)</p><p>(0.031)</p></td><td style="vertical-align:top"><p>670.7</p></td><td style="vertical-align:top"><p>723.7</p></td><td style="vertical-align:top"><p>53.0</p><p>(-2.7, 108.7)</p></td><td style="vertical-align:top"><p>378</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p>* Patients with at least 2 of the following: Cough; purulent sputum, temperature &gt;38&deg;C or &lt;36.1&deg;C; pneumonia (auscultatory findings); leukocytosis; C-reactive protein value &gt;3 times the upper limit of normal; hypoxemia with a partial oxygen pressure &lt;60 mm Hg while breathing room air.&nbsp;</p><p><sup>1 </sup>A Poisson regression model with random effects was used to calculate VE.</p><p><sup>2 </sup>Per 100,000 person-years of observation. IRR is calculated as the incidence in the placebo group minus the incidence in the vaccine group, and was mathematically equivalent to VE &times; the incidence in the placebo group.</p><p><sup>3</sup> Based on a 5-year duration of protection. &nbsp;NNV is not a rate but instead indicates the number of cases prevented for a given number of persons vaccinated. NNV also incorporates the length of the trial or duration of protection and is calculated as 1 divided by the product of the IRR and duration of protection (or length of trial) (=1/(IRR &times; duration).</p></td></tr></tbody></table><p>&nbsp;</p><p>Immunogenicity studies in adults &ge;18 years and the elderly</p><p>&nbsp;</p><p>In adults, an antibody threshold of serotype-specific pneumococcal polysaccharide IgG binding antibody concentration associated with protection has not been defined. For all pivotal clinical trials, a serotype-specific opsonophagocytosis assay (OPA) was used as a surrogate to assess potential efficacy against invasive pneumococcal disease and pneumonia. OPA geometric mean titers (GMTs) measured 1-month after each vaccination were calculated. OPA titres are expressed as the reciprocal of the highest serum dilution that reduces survival of the pneumococci by at least 50&nbsp;%.</p><p>&nbsp;</p><p>Pivotal trials for Prevenar&nbsp;13 were designed to show that functional OPA antibody responses for the 13 serotypes are non-inferior, and for some serotypes superior, to the 12 serotypes in common with the licensed 23-valent pneumococcal polysaccharide vaccine [1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] one month after vaccine administration. The response to serotype 6A, which is unique to Prevenar&nbsp;13, was assessed by demonstration of a 4-fold increase in the specific OPA titer above pre‑immunised levels.</p><p>&nbsp;</p><p>Five clinical studies were conducted in Europe and the USA evaluating the immunogenicity of Prevenar&nbsp;13 in different age groups ranging from 18-95 years of age. Clinical studies with Prevenar&nbsp;13 currently provide immunogenicity data in adults aged 18 years and older, including adults aged 65 and older previously vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine, 5 years prior to enrollment. Each study included healthy adults and immuno-competent adults with stable underlying conditions known to predispose individuals to pneumococcal infection (i.e., chronic cardiovascular disease, chronic pulmonary disease including asthma, renal disorders and diabetes mellitus, chronic liver disease including alcoholic liver disease), and adults with risk factors such as smoking and alcohol abuse.</p><p>&nbsp;</p><p>Immunogenicity and safety of Prevenar&nbsp;13 has been demonstrated in adults aged 18 years and older including those previously vaccinated with a pneumococcal polysaccharide vaccine.</p><p>&nbsp;</p><p>Adults not previously vaccinated with 23‑valent pneumococcal polysaccharide vaccine</p><p>In a head-to-head, comparative trial conducted in adults aged 60-64 years, subjects received a single dose of either Prevenar&nbsp;13 or 23-valent pneumococcal polysaccharide vaccine. In the same study another group of adults aged 50-59 years and another group of adults aged 18-49 years received a single dose of Prevenar&nbsp;13.</p><p>&nbsp;</p><p>Table 7 compares the OPA GMTs, 1-month post-dose, in 60-64 year olds given either a single dose of Prevenar&nbsp;13 or 23-valent pneumococcal polysaccharide vaccine, and in 50-59 year olds given a single dose of Prevenar&nbsp;13.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="8" style="vertical-align:bottom"><p><strong>Table 7: OPA GMTs in adults aged 60-64 years given Prevenar&nbsp;13 or 23</strong>-<strong>valent pneumococcal polysaccharide vaccine (PPSV23) and in adults aged 50-59 years given Prevenar&nbsp;13</strong><sup>a,</sup><sup>b,c</sup></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;13</strong></p></td><td style="vertical-align:bottom"><p><strong>Prevenar&nbsp;13</strong></p></td><td style="vertical-align:bottom"><p><strong>PPSV23</strong></p></td><td colspan="2" rowspan="2"><p><strong>Prevenar&nbsp;13</strong></p><p><strong>50-59 Relative to</strong></p><p><strong>60-64 Years</strong></p></td><td colspan="2" rowspan="2"><p><strong>Prevenar&nbsp;13 Relative</strong></p><p><strong>to PPSV23,</strong></p><p><strong>60-64 Years</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>50-59 Years </strong></p><p><strong>N=350-384</strong></p></td><td style="vertical-align:bottom"><p><strong>60-64 Years </strong></p><p><strong>N=359-404</strong></p></td><td style="vertical-align:bottom"><p><strong>60-64 Years </strong></p><p><strong>N=367-402</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Serotype</strong></p></td><td style="vertical-align:bottom"><p>GMT</p></td><td style="vertical-align:bottom"><p>GMT</p></td><td style="vertical-align:bottom"><p>GMT</p></td><td><p>GMR</p></td><td><p>(95% CI)</p></td><td><p>GMR</p></td><td style="vertical-align:top"><p>(95% CI)</p></td></tr></thead><tbody><tr><td><p>1</p></td><td><p>200</p></td><td><p>146</p></td><td><p>104</p></td><td><p>1.4</p></td><td><p>(1.08, 1.73)</p></td><td><p>1.4</p></td><td><p>(1.10, 1.78)</p></td></tr><tr><td><p>3</p></td><td><p>91</p></td><td><p>93</p></td><td><p>85</p></td><td><p>1.0</p></td><td><p>(0.81, 1.19)</p></td><td><p>1.1</p></td><td><p>(0.90, 1.32)</p></td></tr><tr><td><p>4</p></td><td><p>2833</p></td><td><p>2062</p></td><td><p>1295</p></td><td><p>1.4</p></td><td><p>(1.07, 1.77)</p></td><td><p>1.6</p></td><td><p>(1.19, 2.13)</p></td></tr><tr><td><p>5</p></td><td><p>269</p></td><td><p>199</p></td><td><p>162</p></td><td><p>1.4</p></td><td><p>(1.01, 1.80)</p></td><td><p>1.2</p></td><td><p>(0.93, 1.62)</p></td></tr><tr><td><p>6A<sup>&dagger;</sup></p></td><td><p>4328</p></td><td><p>2593</p></td><td><p>213</p></td><td><p>1.7</p></td><td><p>(1.30, 2.15)</p></td><td><p>12.1</p></td><td><p>(8.63, 17.08)</p></td></tr><tr><td><p>6B</p></td><td><p>3212</p></td><td><p>1984</p></td><td><p>788</p></td><td><p>1.6</p></td><td><p>(1.24, 2.12)</p></td><td><p>2.5</p></td><td><p>(1.82, 3.48)</p></td></tr><tr><td><p>7F</p></td><td><p>1520</p></td><td><p>1120</p></td><td><p>405</p></td><td><p>1.4</p></td><td><p>(1.03, 1.79)</p></td><td><p>2.8</p></td><td><p>(1.98, 3.87)</p></td></tr><tr><td><p>9V</p></td><td><p>1726</p></td><td><p>1164</p></td><td><p>407</p></td><td><p>1.5</p></td><td><p>(1.11, 1.98)</p></td><td><p>2.9</p></td><td><p>(2.00, 4.08)</p></td></tr><tr><td><p>14</p></td><td><p>957</p></td><td><p>612</p></td><td><p>692</p></td><td><p>1.6</p></td><td><p>(1.16, 2.12)</p></td><td><p>0.9</p></td><td><p>(0.64, 1.21)</p></td></tr><tr><td><p>18C</p></td><td><p>1939</p></td><td><p>1726</p></td><td><p>925</p></td><td><p>1.1</p></td><td><p>(0.86, 1.47)</p></td><td><p>1.9</p></td><td><p>(1.39, 2.51)</p></td></tr><tr><td><p>19A</p></td><td><p>956</p></td><td><p>682</p></td><td><p>352</p></td><td><p>1.4</p></td><td><p>(1.16, 1.69)</p></td><td><p>1.9</p></td><td><p>(1.56, 2.41)</p></td></tr><tr><td><p>19F</p></td><td><p>599</p></td><td><p>517</p></td><td><p>539</p></td><td><p>1.2</p></td><td><p>(0.87, 1.54)</p></td><td><p>1.0</p></td><td><p>(0.72, 1.28)</p></td></tr><tr><td><p>23F</p></td><td><p>494</p></td><td><p>375</p></td><td><p>72</p></td><td><p>1.3</p></td><td><p>(0.94, 1.84)</p></td><td><p>5.2</p></td><td><p>(3.67, 7.33)</p></td></tr><tr><td colspan="8"><p><sup>a </sup>Non-inferiority was defined as the lower limit of the 2-sided 95% CI for GMR was greater than 0.5.</p><p><sup>b</sup> Statistically significantly greater response was defined as the lower bound of the 2-sided 95% CI for the GMR was greater than 1.</p><p><sup>c</sup> For serotype 6A<sup>&dagger;</sup>, which is unique to Prevenar&nbsp;13, a statistically significantly greater response was defined as the lower bound of the 2-sided 95% CI for the GMR being greater than 2.</p></td></tr></tbody></table><p>&nbsp;</p><p>In adults aged 60-64 years, OPA GMTs to Prevenar&nbsp;13 were non-inferior to the OPA GMTs elicited to the 23-valent pneumococcal polysaccharide vaccine for the twelve serotypes common to both vaccines. For 9&nbsp;serotypes, the OPA titers were shown to be statistically significantly greater in Prevenar&nbsp;13 recipients.</p><p>&nbsp;</p><p>In adults aged 50-59 years, OPA GMTs to all 13 serotypes in Prevenar&nbsp;13 were non-inferior to the Prevenar&nbsp;13 responses in adults aged 60-64 years. For 9 serotypes, immune responses were related to age, with adults in the 50-59 years group showing statistically significantly greater responses than adults aged 60-64 years.</p><p>&nbsp;</p><p>In all adults &ge;&nbsp;50 years who received a single dose of Prevenar&nbsp;13, the OPA titers to serotype 6A were significantly greater than in adults &ge; 60 years who received a single dose of 23-valent pneumococcal polysaccharide vaccine.</p><p>&nbsp;</p><p>One year after vaccination with Prevenar&nbsp;13 OPA titers had declined compared to one month after vaccination, however, OPA titers for all serotypes remained higher than levels at baseline:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>OPA GMT levels at baseline</p></td><td style="vertical-align:top"><p>OPA GMT levels one year after Prevenar&nbsp;13</p></td></tr><tr><td style="vertical-align:top"><p>Adults 50-59 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5 to 45</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20 to 1234</p></td></tr><tr><td style="vertical-align:top"><p>Adults 60-64 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5 to 37</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19 to 733</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Table 8 shows OPA GMTs 1-month after a single dose of Prevenar&nbsp;13 in 18-49 year olds compared to 60-64 year olds.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="5"><p><strong>Table&nbsp;8: OPA GMTs in adults aged 18-49&nbsp;years and 60-64&nbsp;years given Prevenar 13</strong><sup>a,</sup><sup>b</sup></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>18-49 Years</strong></p><p><strong>N=836-866</strong></p></td><td style="vertical-align:bottom"><p><strong>60-64 Years</strong></p><p><strong>N=359-404</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>18-49 Years </strong></p><p><strong>Relative to </strong></p><p><strong>60-64 Years </strong></p></td></tr><tr><td><p><strong>Serotype</strong></p></td><td style="vertical-align:bottom"><p>GMT<sup>b</sup></p></td><td style="vertical-align:bottom"><p>GMT<sup>b</sup></p></td><td style="vertical-align:bottom"><p>GMR</p></td><td style="vertical-align:bottom"><p>(95% CI<sup>c</sup>)</p></td></tr></thead><tbody><tr><td><p>1</p></td><td><p>353</p></td><td><p>146</p></td><td><p>2.4</p></td><td><p>(2.03, 2.87)</p></td></tr><tr><td><p>3</p></td><td><p>91</p></td><td><p>93</p></td><td><p>1.0</p></td><td><p>(0.84, 1.13)</p></td></tr><tr><td><p>4</p></td><td><p>4747</p></td><td><p>2062</p></td><td><p>2.3</p></td><td><p>(1.92, 2.76)</p></td></tr><tr><td><p>5</p></td><td><p>386</p></td><td><p>199</p></td><td><p>1.9</p></td><td><p>(1.55, 2.42)</p></td></tr><tr><td><p>6A</p></td><td><p>5746</p></td><td><p>2593</p></td><td><p>2.2</p></td><td><p>(1.84, 2.67)</p></td></tr><tr><td><p>6B</p></td><td><p>9813</p></td><td><p>1984</p></td><td><p>4.9</p></td><td><p>(4.13, 5.93)</p></td></tr><tr><td><p>7F</p></td><td><p>3249</p></td><td><p>1120</p></td><td><p>2.9</p></td><td><p>(2.41, 3.49)</p></td></tr><tr><td><p>9V</p></td><td><p>3339</p></td><td><p>1164</p></td><td><p>2.9</p></td><td><p>(2.34, 3.52)</p></td></tr><tr><td><p>14</p></td><td><p>2983</p></td><td><p>612</p></td><td><p>4.9</p></td><td><p>(4.01, 5.93)</p></td></tr><tr><td><p>18C</p></td><td><p>3989</p></td><td><p>1726</p></td><td><p>2.3</p></td><td><p>(1.91, 2.79)</p></td></tr><tr><td><p>19A</p></td><td><p>1580</p></td><td><p>682</p></td><td><p>2.3</p></td><td><p>(2.02, 2.66)</p></td></tr><tr><td><p>19F</p></td><td><p>1533</p></td><td><p>517</p></td><td><p>3.0</p></td><td><p>(2.44, 3.60)</p></td></tr><tr><td><p>23F</p></td><td><p>1570</p></td><td><p>375</p></td><td><p>4.2</p></td><td><p>(3.31, 5.31)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a </sup>Non-inferiority was defined as the lower limit of the 2-sided 95% CI for GMR was greater than 0.5.</p><p><sup>b </sup>Statistically significantly greater response was defined as the lower bound of the 2-sided 95% CI for the GMR was greater than 1.</p><p><sup>c c </sup>Confidence intervals (CIs) for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures.</p></td></tr></tbody></table><p>&nbsp;</p><p>In adults aged 18-49 years, OPA GMTs to all 13 serotypes in Prevenar&nbsp;13 were non-inferior to the Prevenar&nbsp;13 responses in adults aged 60-64 years.</p><p>&nbsp;</p><p>One year after vaccination with Prevenar&nbsp;13 OPA titers had declined compared to one month after vaccination, however OPA titers for all serotypes remained higher than levels at baseline.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>OPA GMT levels at baseline</p></td><td style="vertical-align:top"><p>OPA GMT levels one year after Prevenar 13</p></td></tr><tr><td style="vertical-align:top"><p>Adults 18-49 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5 to 186</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23 to 2948</p></td></tr></tbody></table><p>&nbsp;</p><p>Adults previously vaccinated with 23‑valent pneumococcal polysaccharide vaccine</p><p>Immune responses to Prevenar&nbsp;13 and 23-valent pneumococcal polysaccharide vaccine were compared in a head to head trial in adults aged &ge;&nbsp;70 years, who had received a single dose of pneumococcal polysaccharide vaccine at least&nbsp;5 years before study vaccination.</p><p>&nbsp;</p><p>Table 9 compares the OPA GMTs, 1-month post-dose, in pneumococcal polysaccharide vaccinated adults aged &ge;&nbsp;70 years given a single dose of either Prevenar&nbsp;13 or 23-valent pneumococcal polysaccharide vaccine.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table 9: OPA GMTs in pneumococcal polysaccharide vaccinated adults aged </strong></p><p><strong>&ge;&nbsp;70&nbsp;years given either Prevenar 13 or 23</strong>-<strong>valent pneumococcal polysaccharide vaccine (PPSV23)</strong><sup>a,</sup><sup>b,c</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Prevenar 13</strong></p><p><strong>N=400-426</strong></p></td><td style="vertical-align:bottom"><p><strong>PPSV23</strong></p><p><strong>N=395-445</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Prevenar OPA GMT</strong></p><p><strong>Relative to PPSV23</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Serotype</strong></p></td><td style="vertical-align:bottom"><p>OPA GMT</p></td><td style="vertical-align:bottom"><p>OPA GMT</p></td><td style="vertical-align:bottom"><p>GMR</p></td><td style="vertical-align:bottom"><p>(95% CI)</p></td></tr><tr><td><p>1</p></td><td><p>81</p></td><td><p>55</p></td><td><p>1.5</p></td><td><p>(1.17, 1.88)</p></td></tr><tr><td><p>3</p></td><td><p>55</p></td><td><p>49</p></td><td><p>1.1</p></td><td><p>(0.91, 1.35)</p></td></tr><tr><td><p>4</p></td><td><p>545</p></td><td><p>203</p></td><td><p>2.7</p></td><td><p>(1.93, 3.74)</p></td></tr><tr><td><p>5</p></td><td><p>72</p></td><td><p>36</p></td><td><p>2.0</p></td><td><p>(1.55, 2.63)</p></td></tr><tr><td><p>6A<sup>&dagger;</sup></p></td><td><p>903</p></td><td><p>94</p></td><td><p>9.6</p></td><td><p>(7.00, 13.26)</p></td></tr><tr><td><p>6B</p></td><td><p>1261</p></td><td><p>417</p></td><td><p>3.0</p></td><td><p>(2.21, 4.13)</p></td></tr><tr><td><p>7F</p></td><td><p>245</p></td><td><p>160</p></td><td><p>1.5</p></td><td><p>(1.07, 2.18)</p></td></tr><tr><td><p>9V</p></td><td><p>181</p></td><td><p>90</p></td><td><p>2.0</p></td><td><p>(1.36, 2.97)</p></td></tr><tr><td><p>14</p></td><td><p>280</p></td><td><p>285</p></td><td><p>1.0</p></td><td><p>(0.73, 1.33)</p></td></tr><tr><td><p>18C</p></td><td><p>907</p></td><td><p>481</p></td><td><p>1.9</p></td><td><p>(1.42, 2.50)</p></td></tr><tr><td><p>19A</p></td><td><p>354</p></td><td><p>200</p></td><td><p>1.8</p></td><td><p>(1.43, 2.20)</p></td></tr><tr><td><p>19F</p></td><td><p>333</p></td><td><p>214</p></td><td><p>1.6</p></td><td><p>(1.17, 2.06)</p></td></tr><tr><td><p>23F</p></td><td><p>158</p></td><td><p>43</p></td><td><p>3.7</p></td><td><p>(2.69, 5.09)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup> Non-inferiority was defined as the lower limit of the 2-sided 95% CI for GMR was greater than 0.5.</p><p><sup>b</sup> Statistically significantly greater response was defined as the lower bound of the 2-sided 95% CI for the GMR was greater than 1.</p><p><sup>c </sup>For serotype 6A<sup>&dagger;</sup>, which is unique to Prevenar&nbsp;13, a statistically significantly greater response was defined as the lower bound of the 2-sided 95% CI for the GMR greater than 2.</p></td></tr></tbody></table><p>&nbsp;</p><p>In adults vaccinated with pneumococcal polysaccharide vaccine at least&nbsp;5 years prior to the clinical study, OPA GMTs to Prevenar&nbsp;13 were non-inferior to the 23-valent pneumococcal polysaccharide vaccine responses for the 12&nbsp;serotypes in common. Furthermore, in this study statistically significantly greater OPA GMTs were demonstrated for 10 of the 12 serotypes in common. Immune responses to serotype 6A were statistically significantly greater following vaccination with Prevenar&nbsp;13 than after 23-valent pneumococcal polysaccharide vaccine.</p><p>&nbsp;</p><p>One year after vaccination with Prevenar&nbsp;13 in adults aged 70 years and over who were vaccinated with 23-valent pneumococcal polysaccharide vaccine, at least 5 years prior to study entry, OPA titers had declined compared to one month after vaccination, however, OPA titers for all serotypes remained higher than levels at baseline:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>OPA GMT levels at baseline</p></td><td style="vertical-align:top"><p>OPA GMT levels one year after Prevenar&nbsp;13</p></td></tr><tr><td style="vertical-align:top"><p>Adults &ge; 70 years vaccinated with 23-valent pneumococcal polysaccharide vaccine at least 5 years prior</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9 to 122</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>18 to 381</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Immune responses in Special Populations</u></p><p>&nbsp;</p><p>Individuals with the conditions described below have an increased risk of pneumococcal disease. The clinical relevance of the antibody levels elicited by Prevenar&nbsp;13 in these special populations is unknown.</p><p>&nbsp;</p><p><em>Sickle cell disease </em></p><p>An open label single arm study in France, Italy, UK, US, Lebanon, Egypt and Saudi Arabia with 2&nbsp;doses of Prevenar&nbsp;13 given 6 months apart was conducted in 158 children and adolescents &ge; 6 to &lt;&nbsp;18&nbsp;years of age with sickle cell disease who were previously vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine at least 6 months prior to enrollment. After the first vaccination, Prevenar&nbsp;13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination. After the second dose immune responses were comparable to those after the first dose. One year after the second dose, antibody levels measured by both IgG GMCs and OPA GMTs were higher than levels prior to the first dose of Prevenar&nbsp;13, except for the IgG GMCs for serotypes 3 and 5 that were numerically similar.</p><p>&nbsp;</p><p><em>Additional Prevenar (7-valent) immunogenicity data: children with sickle cell disease</em></p><p>The immunogenicity of Prevenar has been investigated in an open-label, multicentre study in 49&nbsp;infants with sickle cell disease. Children were vaccinated with Prevenar (3 doses one month apart from the age of 2 months), 46 of these children also received a 23-valent pneumococcal polysaccharide vaccine at the age of 15-18 months. After primary immunisation, 95.6 % of the subjects had antibody levels of at least 0.35 &mu;g/ml for all seven serotypes found in Prevenar. A&nbsp;significant increase was seen in the concentrations of antibodies against the seven serotypes after the polysaccharide vaccination, suggesting that immunological memory was well established.</p><p>&nbsp;</p><p><em>HIV infection</em></p><p><em>&nbsp;</em></p><p><em><u>Children and adults not previously vaccinated with a pneumococcal vaccine</u></em></p><p>HIV-infected children and adults with CD4 &ge; 200 cells/&micro;L (mean 717.0&nbsp;cells/&mu;L), viral load &lt;&nbsp;50,000&nbsp;copies/ml (mean 2090.0 copies/ml), free of active AIDS-related illness and not previously vaccinated with&nbsp;a&nbsp;pneumococcal vaccine received 3 doses of Prevenar&nbsp;13. As per general recommendations, a single dose of 23-valent pneumococcal polysaccharide vaccine was subsequently administered. Vaccines were administered at 1 month intervals. Immune responses were assessed in 259-270 evaluable subjects approximately 1 month after each dose of vaccine. After the first dose, Prevenar&nbsp;13 elicited antibody levels, measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination. After the second and third dose of Prevenar&nbsp;13, immune responses were similar or higher than those after the first dose.</p><p><em>&nbsp;</em></p><p><em><u>Adults previously vaccinated with 23-valent pneumococcal polysaccharide vaccine</u></em></p><p>HIV-infected adults &ge; 18 years of age with CD4 &ge; 200 cells/&micro;L (mean 609.1 cells/&micro;L) and viral load &lt;&nbsp;50,000 copies/ml (mean 330.6 copies/ml), who were free of active AIDS-related illness and were previously vaccinated with 23-valent pneumococcal polysaccharide vaccine administered at least 6&nbsp;months prior to enrollment, received 3 doses of Prevenar&nbsp;13, at enrollment, 6 months, and 12&nbsp;months after the first dose of Prevenar&nbsp;13. Immune responses were assessed in 231-255 evaluable subjects approximately 1&nbsp;month after each dose of Prevenar&nbsp;13. After the first dose, Prevenar&nbsp;13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination. After the second and third dose of Prevenar&nbsp;13, immune responses were comparable or higher than those after the first dose. In the study 162 subjects had received one prior dose of 23-valent pneumococcal polysaccharide vaccine, 143&nbsp;subjects 2 prior doses and 26 subjects more than 2 prior doses of 23-valent polysaccharide vaccine. Subjects who received two or more previous doses of 23-valent pneumococcal polysaccharide vaccine showed a similar immune response compared with subjects who received a single previous dose.</p><p>&nbsp;</p><p><em>Haematopoietic stem cell transplant</em></p><p>Children and adults with an allogeneic haematopoietic stem cell transplant (HSCT) at &ge;&nbsp;2&nbsp;years of age with complete haematologic remission of underlying disease or with very good partial remission in the case of lymphoma and myeloma received three doses of Prevenar&nbsp;13 with an interval of at least 1&nbsp;month between doses. The first dose was administered at 3 to 6 months after HSCT. A fourth (booster) dose of Prevenar&nbsp;13 was administered 6 months after the third dose. As per general recommendations, a single dose of 23‑valent pneumococcal polysaccharide vaccine was administered 1 month after the fourth dose of Prevenar&nbsp;13. Immune responses as measured by IgG GMCs were assessed in 168-211 evaluable subjects approximately 1 month after vaccination. Prevenar&nbsp;13 elicited increased antibody levels after each dose of Prevenar&nbsp;13. Immune responses after the fourth dose of Prevenar&nbsp;13 were significantly increased for all serotypes compared with after the third dose. Functional antibody titers (OPA titers) were not measured in this study.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity, local tolerance, and reproduction and developmental toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride: 4.25mg</p><p>Succinic acid: 0.295mg</p><p>Polysorbate 80: 0.1mg</p><p>Water for injections: qs to 0.5ml</p><p>&nbsp;</p><p>For adjuvant, see section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

	Do not use Prevenar 13 after the expiry date which is stated on the carton /Vial Label after EXP: The expiry date refers to the last day of that month.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5&nbsp;ml suspension for injection in pre-filled syringe (Type I glass) with a plunger stopper (latex-free chlorobutyl rubber)&nbsp;and protective-tip cap (latex-free isoprene bromobutyl rubber).</p><p>&nbsp;</p><p>Pack sizes of 1 and 10, with or without&nbsp;needle, and a multipack of 5 packs, each containing 10&nbsp;pre‑filled syringes, with or without needle.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During storage, a white deposit and clear supernatant can be observed. This does not constitute a sign of deterioration.</p><p>&nbsp;</p><p>The vaccine should be shaken well to obtain a homogeneous white suspension prior to expelling air from the syringe, and should be inspected visually for any particulate matter and/or variation of physical aspect prior to administration. Do not use if the content appears otherwise.</p><p>&nbsp;</p><p>No special requirements for disposal.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Europe MA EEIG, Belgium
MANUFACTURED BY:
Pfizer Ireland Pharmaceuticals, 
Grange Castle Business Park, 
Clondalkin, Dublin 22, 
Ireland 

PACKED & RELEASED BY:
Pfizer Manufacturing Belgium NV
Rijksweg 12
2870, Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>